Cell Therapy for Neurological Disorders: The Perspective of Promising Cells

Donghui Liu, Larisa Bobrovskaya and Xin-Fu Zhou *

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5000, Australia; liudy016@mymail.unisa.edu.au (D.L.); Larisa.Bobrovskaya@unisa.edu.au (L.B.)
* Correspondence: xin-fu.zhou@unisa.edu.au

Simple Summary: Cell therapy has become a powerful method for regenerative medicine. However, there has not been an ideal cell type and cell source for the treatment of neurological diseases such as Parkinson’s disease and Alzheimer’s disease. This review aims to introduce the potentials of different cells for treating neurological disorders by collecting the results from related clinical trials and recent animal studies. It is an overview of some promising cells that may be clinically used for neurological disorders. The characteristics of each cell type and the main mechanism of function are also described.

Abstract: Neurological disorders are big public health challenges that are affecting hundreds of millions of people around the world. Although many conventional pharmacological therapies have been tested in patients, their therapeutic efficacies to alleviate their symptoms and slow down the course of the diseases are usually limited. Cell therapy has attracted the interest of many researchers in the last several decades and has brought new hope for treating neurological disorders. Moreover, numerous studies have shown promising results. However, none of the studies has led to a promising therapy for patients with neurological disorders, despite the ongoing and completed clinical trials. There are many factors that may affect the outcome of cell therapy for neurological disorders due to the complexity of the nervous system, especially cell types for transplantation and the specific disease for treatment. This paper provides a review of the various cell types from humans that may be clinically used for neurological disorders, based on their characteristics and current progress in related studies.

Keywords: cell therapy; cell transplantation; neurological disorders; stem cells; clinical trials

1. Introduction

Neurological disorders are defined as diseases of the nervous system. There are more than 600 neurological disorders that can be divided into four categories: (1) sudden onset conditions, such as stroke; (2) intermittent conditions, such as epilepsy; (3) progressive conditions, such as Parkinson’s disease (PD); (4) stable neurological conditions, such as cerebral palsy. These diseases have become a big public health challenge and present a tremendous burden to individuals, their families, and society. Some of the disorders can be common and severe, including stroke, Huntington’s disease (HD), traumatic brain injury (TBI), spinal cord injury (SCI), epilepsy, PD, Alzheimer’s disease (AD), Lyme disease, cerebral palsy, ataxia, amyotrophic lateral sclerosis (ALS), hypoxic-ischemic encephalopathy (HIE) and multiple sclerosis (MS). Currently, although there are many conventional therapies that can alleviate their symptoms, such as levodopa or deep brain stimulation for PD [1], cholinesterase inhibitors, or memantine for AD [2], these treatments have failed to slow or reverse the progression of the diseases, in other words, these diseases are not curable by the conventional therapies.

A common feature of many severe neurological disorders is the loss and/or dysfunction of massive neural cells, especially neurons. Therefore, regenerative medicine,
especially cell therapy, has become an intriguing field for researchers in the last several decades. Cell therapy is thought to be an excellent therapy for many neurological disorders acting by replacing dead cells or/and releasing protective factors to the damaged cells or/and modulating the lesion’s microenvironment in the nervous system [3–5]. With the rapidly expanding studies in this research area, cell therapy has shown its unique potentials in treating neurological disorders. Currently, various types of cells have been used in cell therapy studies, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), neural stem/progenitor cells (NSPCs), mesenchymal stromal/stem cells (MSCs), and olfactory ensheathing cells (OECs), etc. However, despite the promising results from numerous animal-based studies, the outcomes from clinical trials are normally not as significant as from animal studies. This may be due to the difference between animal models and the real disease of patients and the differences in nervous systems between animals and humans.

The outcome of cell therapy can be affected by many factors, including cell source, cell type, route of administration, and the target disease. The aim of this review is to summarize the cells that may be clinically used for neurological disorders, especially for the diseases mentioned above, and their characteristics and current progresses in related studies.

2. Cell Source: Autologous or Allogeneic?

The transplantable cells for patients can be divided into two sources: autologous and allogeneic. Autologous cells are usually more favorable than allogeneic cells in regenerative medicine as they avoid several issues that allogeneic cells may have, such as immune rejection or the use of immunosuppressants, ethical issues, and finding suitable donors [6]. However, allogeneic transplants are necessary for the cells that are therapeutic but hard to obtain from the patients themselves, such as ESCs [7], NSPCs [8], and fetal stem cells (FSCs) that contain various stem cells from fetal blood and tissues (e.g., MSCs, NSPCs, and hematopoietic stem cells) (see Table 1). Nowadays, cell reprogramming provides a new opportunity to generate any type of autologous cells from another type of easily obtainable somatic cells, such as iPSCs from urine [9] and induced neural stem cells from fibroblasts [10]. However, the safety of these cells is highly related to the methods and vectors used in induction protocols [11–13], and the safety and therapeutic effects need to be well studied before taking into clinical application.

Table 1. Differences between autologous transplantation and allogeneic transplantation.

| Cell Source          | Additional Invasive Procedures | Immunogenicity       | Ethical Issues | Cell Availability                        | Cell Type                           |
|----------------------|--------------------------------|----------------------|----------------|------------------------------------------|-------------------------------------|
| Autologous transplantation | Patients themselves          | Yes                  | No immune rejection | Limited by autologous cell culture | Limited, depending on the patient himself/herself |
| Allogeneic transplantation | Other donors                 | No                   | Activated immune response, immunosuppressants required | Cryopreserved stocks, suitable for big amount cell preservation | Various, depending on the donors (e.g., ESCs and FSCs) |

Interestingly, some cells, such as umbilical cord blood mononuclear cells and adipose-derived mesenchymal stem cells (hADSCs), have been reported as immature immune cells; namely, they will not cause immune rejection, even in the absence of immune suppression [14,15], which may make them suitable candidates as allogeneic transplants.

3. Different Cell Types and the Current Progress

3.1. Embryonic Stem Cells (hESCs)

Human ESCs (hESCs) are pluripotent cells that are derived from human embryos and are capable of self-renewing and differentiating into all types of human cells. The first
cell line of hESCs was isolated by James Thomson in 1998 [16], which then brought a new hope of developing new hESC lines for cell therapy. The therapeutic potential of ESCs for neurological disorders was proved a long time ago [17,18]. However, several critical issues of hESCs have limited the related studies and clinical applications: (1) ethical issues, as the establishment of hESCs lines involves the exploitation and destruction of human embryos; (2) immune rejection. As hESCs are allogeneic cells, they may cause immune rejection after transplantation [19], or the patient may need a life-long administration of immunosuppressants; (3) tumor formation. Due to the pluripotency of hESCs, they have the potential to generate teratoma after transplantation [20,21]. Several methods have been reported to reduce or eliminate the tumorigenicity of ESCs, such as pre-treating ESCs with mitomycin [22], co-transplantation ESCs with MSCs [23]. Among these methods, pre-differentiating ESCs into target cells prior to transplantation is a favorable way. hESCs are normally taken as a source of different cells in vitro. hESCs derivates, such as hESCs-derived oligodendrocytes, hESCs-derived dopaminergic neurons, have shown their therapeutic effects in animal studies for treating neurological disorders [24,25]. Although several animal studies transplanting hESCs for neurological disorders (such as SCI [26]) have shown some therapeutic effects, hESCs are normally considered unlikely to be directly grafted for cell therapy. Remarkably, however, Geeta Shroff has transplanted hESCs via a similar cell delivery method into patients with Lyme disease, multiple sclerosis, spinal cord injury, stroke, or cerebral palsy, and has proved the effectiveness and safety of the cells (see Table 2), with some ethical concerns [27,28]. Moreover, it has been claimed that these hESCs prepared at their institute are unlikely to cause immune rejection even without immunosuppressants as they were harvested at the very initial stage of blastocyst when the genesis was not activated [7]. To summarize, hESCs are more used as a source of other transplantable cells rather than a direct transplantation candidate in cell therapy studies. However, a certain line of hESCs may become a suitable candidate for cell therapy for neurological disorders if the critical issues can be overcome in the future.

| Disease                        | Route of Administration | Cell Source | Cell Amount       | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion                                                                 | Ref. |
|--------------------------------|-------------------------|-------------|-------------------|--------------------|---------------------------------------------------|-----------------------------------------------------------------------------------|------|
| Lyme disease                   | Intramuscular, intravenous, and other supplemental routes | Human embryo | N/A               | 59                 | 8 weeks                                           | 43 patients showed significant improvement, 12 patients showed moderate improvement, 4 patients exhibited mild improvement in their brain perfusion; no deterioration was found | [29] |
| Lyme disease and multiple sclerosis | Intramuscular, intravenous, and other supplemental routes | Human embryo | N/A               | 2                  | N/A                                               | Patients showed remarkable neurological functional and histological improvement; no adverse events were reported | [30] |
| Spinal cord injury             | Intramuscular, intravenous, and other supplemental routes | Human embryo | hundreds of millions of cells in total | 5                  | 5 years                                           | All patients showed neurological functional improvement, 3/5 showed improved American Spinal Injury Association score (ASIA); no adverse events were reported | [31] |
| Spinal cord injury             | Intramuscular, intravenous, and other supplemental routes | Human embryo | hundreds of millions of cells in total | 226                | N/A                                               | 70% of patients improved by at least one ASIA grade after 3 phases of treatment; no adverse events were reported | [32] |
| Stroke                         | Intramuscular, intravenous, and other supplemental routes | Human embryo | hundreds of millions of cells in total | 24                 | N/A                                               | A large population of patients saw significant improvement regarding Nutech Functional Score and European Stroke Scale; no adverse events were reported | [33] |
Table 2. Cont.

| Disease          | Route of Administration | Cell Source       | Cell Amount                  | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion                                                                 | Ref. |
|------------------|-------------------------|-------------------|------------------------------|--------------------|---------------------------------------------------|-----------------------------------------------------------------------------------|------|
| Multiplesclerosis| Intramuscular, intravenous, and other supplemental routes | Human embryo     | hundreds of millions of cells in total | 24                 | Around 1 year                                     | Patients showed an improvement in parameters associated with MS when evaluated with reverse nutech functional score but not with the expanded disability status scale; no adverse events were reported | [27] |
| Cerebral palsy   | Intramuscular, intravenous, and other supplemental routes | Human embryo     | hundreds of millions of cells in total | 91                 | N/A                                               | Most patients showed significant improvement in Gross Motor Function Classification Scores Expanded and Revised (GMFCS-E & R) | [34] |

3.2. Induced Pluripotent Stem Cells (iPSCs)

The first human iPSCs (hiPSCs) line was generated by Takahashi et al. [35] after they introduced four factors (Oct3/4, Sox2, Klf4, and c-Myc) into human fibroblasts. hiPSCs share similarities with hESCs in many aspects such as proliferation, morphology, gene expression, and differentiation. This iPSCs technique (also called cell reprogramming) provides an opportunity to generate any type of patient-specific cells from other obtainable cells, such as fibroblasts or urine cells. Therefore, there are no ethical issues from hiPSCs. Moreover, autologous cells transplantation from patients themselves has no risk of immune rejection and no need to use immunosuppressants. However, there is still the risk of tumor formation [21]. iPSCs are classically generated by the integration of transcription factors with a viral vector, which may cause tumorigenesis and/or unpredictable mutagenesis in the genome. hiPSCs generated by non-integration methods, such as mRNA [36], plasmid [37], small molecules [38], are safer candidates for transplantation, although they are normally with comparatively low reprogramming efficiency [39].

To date, although several animal studies grafting hiPSCs have shown their therapeutic effects for neurological disorders, such as stroke and SCI [5,40] (see Table S1), similar to hESCs, hiPSCs are also usually taken as a source of other transplantable cells in vitro. Pre-differentiated hiPSCs, including hiPSCs-derived NSPCs, hiPSCs-derived neurons and hiPSCs-derived MSCs have been shown effective for neurological disorders [41–43]. Especially, several clinical trials based on hiPSCs derivates have been launched for the treatment of PD and SCI [44,45], and thus have deeply encouraged the use of hiPSCs in treating neurological disorders. However, it is noteworthy that hiPSCs-derived NSPCs may still have the potential to generate tumors [46]. The safety issues, including tumorigenicity and aberrant reprogramming of the cells, need to be clearly addressed before their clinical application.

3.3. Neural Stem/Progenitor Cells (NSPCs)

NSPCs are multipotent cells that can self-renew and generate the main types of cells making up the central nervous system (CNS), including neurons, oligodendrocytes, and astrocytes. NSPCs have a lower risk of tumor formation compared to ESCs and iPSCs as they are more specialized cells and have less self-renewing ability. Therefore, human NSPCs (hNSPCs) are considered a favorable candidate for treating neurological disorders. Although it has been shown that a subset of NSPCs is present in highly restricted regions during adult life, their proliferation declines with aging [47,48], and it is nearly impossible to isolate autologous hNSPCs for cell therapy. The common sources of hNSPCs for research are human fetuses, hESCs, hiPSCs, or hMSCs. Like hESCs, hNSPCs directly isolated from embryos or differentiated from hESCs also have ethical concerns and may cause immune rejection, and hNSPCs from hiPSCs may have the same issues as hiPSCs as mentioned above. hNSPCs can also be obtained by trans-differentiation from hMSCs under specific experimental conditions [49]. In addition, hMSCs-derived hNSPCs are normally preferred
in clinical studies as they normally have fewer issues than those from hESCs or hiPSCs. However, it is still important to generate a stable, efficient, and standardized protocol to convert hMSCs to hNSPCs and study the similarity between hMSCs-derived hNSPCs and bona fide hNSPCs.

Currently, hundreds of animal studies have used hNSPCs for treating various neurological disorders, including stroke, SCI, TBI, PD, HD (see Table S2), which are far more than hESCs or hiPSCs transplantation studies. Moreover, their effectiveness has been proved and reported better than human MSCs in some conditions [50,51]. The grafted hNSPCs can not only differentiate into neurons and glia cells and establish a graft-host connection [52,53] but also produce trophic factors and modulate lesion microenvironment to improve behavior recovery [54,55]. Intriguingly, even the injection of hNSPCs secretome alone has been reported to support the functional recovery of 6-hydroxydopamine (6-OHDA) PD rats [56]. Many methods have been applied to enhance the therapeutic effects of hNSPCs, such as genetically modified hNSPCs by overexpressing a selected trophic factor. Brain-derived neurotrophic factor (BDNF)-overexpressing hNSPCs, glial cell line-derived neurotrophic factor (GDNF)-overexpressing hNSPCs, and insulin-like growth factor 1 (IGF-1)-overexpressing hNSPCs have all been shown significant therapeutic effects on neurological disorders [57–59]. In addition, pre-treating hNSPCs with a gamma-secretase inhibitor [60], metformin [61] or tumor necrosis factor alpha (TNFα) [62], co-transplantation of hNSPCs with MSCs [63] or using biomaterial scaffolds as a carrier for hNSPCs [54,65] have also been reported to improve their therapeutic potential for neurological diseases. However, it is worth noting that the subtype of hNSPCs may also influence their therapeutic effects for a specific disease. For example, the human fetal spinal cord-derived NSPCs or spinal cord-type NSPCs from hiPSCs have all been shown significant therapeutic effects on neurological disorders [57–59].

To date, some clinical studies have been accomplished, and a few have shown beneficial outcomes after hNSPCs transplantation for neurological disorders (see Table 3). For allogeneic transplantation, focusing on specific hNSPC lines may help to keep the consistency of the outcomes from bench to beside. Several clinical-grade hNSPC lines have been applied in clinical trials, including NSI-566. NSI-566 cell line has been shown to be safe and potential effective in ALS patients [67,68] and now is in a phase 3 trial for treating ALS. Moreover, the NSI-566 cell line has also been reported to significantly improve the behavioral and histological recovery of ischemic stroke patients [69]. On the other hand, hNSPCs from autologous MSCs are a preferred candidate for clinical therapies of neurological disorders and have been applied for treating cerebral palsy, MS and TBI, in clinical trials [70–73]. However, most of the trials are in phase 1 or 2 stages, which have proved the safety but not the statistical therapeutic effects of the cells. Further studies need to be performed to better understand the therapeutic effects of the cells for neurological disorders.

Induced neural stem/progenitor cells (iNSPCs), such as iPSCs, are generated from other types of somatic cells (such as fibroblasts or urine cells) but bypass the pluripotency stage. Generation of hiNSPCs is an attractive field and is more favorable than hiPSCs in treating neural diseases, as they are easier to differentiate into terminal neural cells and less tumorigenic. Currently, many hiNSPC lines have been generated through different methods [74,75], and several lines have been tested in animal disease models, such as SCI, glioblastoma, and stoke and have shown their significant therapeutic effects [76–79]. However, the safety and therapeutic potential of hiNSPC are highly related to the induction protocol and need to be further studied. Therefore, it is essential to establish a safe, stable, and efficient protocol to generate hiNSPC for cell therapy studies.
Table 3. Examples of hNSPC transplantation for neurological disorders in clinical trials (data from PubMed).

| Disease (Model)          | Route of Administration | Cell Source                          | Cell Amount            | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion                                                                 | Ref.  |
|-------------------------|-------------------------|--------------------------------------|------------------------|--------------------|---------------------------------------------------|------------------------------------------------------------------------------------|-------|
| Ischemic stroke         | Intracerebral           | Human fetal spinal cord, cell line: NSI-566 | $1.2 \times 10^6$, $2.4 \times 10^6$, or $7.2 \times 10^6$ | 9                  | 24 months                                         | All patients showed significant behavioral and histological improvements          | [69]  |
| ALS                     | Intraspinal             | Human fetal brain                    | $2.25-4.6 \times 10^6$ | 18                 | 51 months                                         | No serious adverse effects. Some patients showed temporary subjective clinical improvement | [80]  |
| ALS                     | Intraspinal             | Human spinal cord                    | 2 to 16 million        | 15                 | 9 months                                          | Intraspinal transplantation of human spinal cord-derived neural stem cells can be safely accomplished at high doses | [81]  |
| ALS                     | Intraspinal             | Human fetal spinal cord, cell line: NSI-566RSC | 1.5 million            | 15                 | 30 months                                         | This NSPCs line can be safely transplanted into both lumbar and/or cervical human spinal cord segments | [67]  |
| moderate PD             | Intracerebral           | Human fetal brain                    | 2 million              | 7                  | 4 years                                           | No adverse effects; enhanced midbrain dopaminergic activity; minor neuropsychological changes; 6/7 showed improved motor function; 5/7 showed better response to medication | [82]  |
| Chronic cervical SCI    | Intraspinal             | Cells were prepared and released by StemCells Inc. | 15 to 40 million       | 16                 | 1 year                                            | Cell transplantation was safe, feasible, and well tolerated. Trends toward improvement in motor function and spasticity were seen | [83]  |
| complete thoracic SCI   | Intraspinal             | Human fetal spinal cord, cell line: NSI-566 | N/A                    | 4                  | 27 months                                         | No serious adverse events; 3/4 showed early signs of potential efficacy            | [68]  |
| Chronic cervical and thoracic SCI | Intraspinal | Human fetal brain, cell line: HuCNS-SC | 20 to 40 million       | 29                 | 1 year                                            | Cell transplantation was safe and feasible using a manual injection technique     | [84]  |
| Traumatic cervical SCI  | Intraspinal             | Human fetal telencephalon            | $1 \times 10^9$        | 34                 | 1 year                                            | No serious adverse effects, 5/19 of treated patients showed functional recovery, 1/15 untreated patients showed functional recovery | [85]  |
| MS                      | Intrathecal             | Autologous MSCs                      | $3 \times 10^7$        | 20                 | Around 1 year                                     | No serious adverse effects, improved median Expanded Disability Status Scale (EDSS), 70% and 50% of the subjects demonstrated improved muscle strength and bladder function, respectively | [73]  |
| MS                      | Intrathecal             | Autologous bone marrow MSCs          | 0.08–17.6 million      | 6                  | 8.9 years                                         | No serious adverse events; 4/6 showed a measurable clinical improvement            | [71]  |
| non-acute severe TBI    | Intravenous or intrathecal | Autologous MSCs                      | 20 to 40 million       | 10                 | 6 months                                          | No serious adverse events, 7/10 patients presented different degrees of improvement in neurological function | [72]  |
| Cerebral palsy          | subarachnoid cavity     | Autologous bone marrow MSCs          | $1-2 \times 10^7$      | 60                 | 6 months                                          | No serious adverse events. Treated group showed significant motor function recovery but no significant increases in the language quotients | [70]  |

3.4. Neurons, Oligodendrocytes, and Astrocytes

Neurons, oligodendrocytes, and astrocytes are three main cell types that form the CNS and originate from a common lineage of hNSPCs during development. These cells are terminal cells from NSPCs differentiation and can also be obtained from human embryos, hESCs, hiPSCs, or hMSCs in cell therapy studies. Transplantation of these pre-differentiated cells can avoid unexpected or unwanted differentiation or tumor formation of stem cells in vivo, especially in neurological disorders that are associated with the loss or dysfunction of specific types of neural cells, such as transplantation of dopaminergic neurons or dopaminergic progenitors for PD. It has been reported that pre-differentiated GABAe-
gic neurons from hNSPCs have shown greater repopulation of the damaged brain and better neurogenic activity and functional recovery than hNSPCs in a stroke model after transplantation, while hNSPCs have predominantly differentiated into astrocytes [86].

Because neurons are the main functional cells in the nervous system, they are usually more attractive than glia cells for regenerative medicine in neuroscience research. Studies have transplanted neurons or neuron progenitors into different disease models and have shown their therapeutic outcomes (see Table S3). However, it is believed that more mature/differentiated donor cells have less survival capacity after transplantation [87–89]. Therefore, for a specific neuron type transplantation (for example, dopaminergic neurons), an immature stage of the cells may lead to better outcomes than mature cells or progenitors [89–91]. In addition, as the pre-differentiated cells have less proliferation capacity, they may need more cells for transplantation to reach a therapeutic level. Remarkably, several clinical trials transplanting neurons or neuron-contained tissue have proved the survival and potential therapeutic effects in patients (see Table 4). Moreover, direct reprogramming of human neurons from other somatic cells may also provide a suitable source of therapeutic neurons for cell therapies [92,93].

Oligodendrocytes and astrocytes are glia cells that are thought of as supportive and protective cells in the nervous system. A recent study has shown that the conditioned medium from hiPSCs-derived glial progenitor cells could result in better therapeutic effects than that from hiPSCs-derived neuronal progenitor cells and show a higher content of neurotrophins, indicating their potentials for cell therapy [94]. The main function of oligodendrocytes is to form myelin sheaths to support and insulate axons. Therefore, oligodendrocytes are highly related to diseases involving demyelination, such as MS and ALS. It has been suggested that transplantation of human oligodendrocyte precursor cells (hOPCs) could result in notable therapeutic outcomes in animals with MS or SCI [95–97], whereas transplantation of mature oligodendrocytes has failed to remyelinate naked axons in SCI [98,99]. Therefore, transplantation of hOPCs may be a potential therapy for demyelinating diseases. On the other hand, astrocytes are the most numerous cell type in the brain, playing various functions, including maintaining homeostasis, providing neurotrophic support, and connecting neurons with the bloodstream [100]. The loss or dysfunction of astrocytes is related to many neurological disorders, such as stroke, epilepsy, and MS [101]. Moreover, the astrocyte-formed glial scars are a reason that prevents neuroregeneration after CNS injury [102]. However, a study has also reported functional recovery after grafting hiPSCs-derived astrocytes with overexpressing the major glutamate transporter, GLT1, in an SCI model, suggesting their pro-regenerative function [103]. Notably, it is reported that the therapeutic effects of astrocytes are highly related to the subtypes of the cells. Stephen et al. found that astrocytes generated from human glial precursor cells by exposure to bone morphogenetic protein could promote significant functional recovery after SCI, whereas astrocytes generated by exposing the cells to ciliary neurotrophic factor failed to generate similar results [104]. Overall, the number of transplantation studies targeting oligodendrocytes or astrocytes is much lower than neuron-based studies. However, with better understanding of their functions in CNS, and more accessible sources of human oligodendrocytes or astrocytes (e.g., from hiPSCs), transplantation of oligodendrocytes or astrocytes may be a promising approach for treating specific neurological disorders.
### Table 4. Examples of neuron transplantation for neurological disorders in clinical trials (data from PubMed).

| Cell Type                      | Disease (Model) | Route of Administration | Cell Source                           | Cell Amount | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion                                                                                   | Ref.     |
|-------------------------------|-----------------|-------------------------|---------------------------------------|-------------|-------------------|---------------------------------------------------|------------------------------------------------------------------------------------------------------|---------|
| sympathetic neurons           | PD              | Intracerebral           | Autologous sympathetic neurons         | N/A         | 4                 | 36 months,                                        | Clinical evaluations showed that an increase in the duration of levodopa-induced “on” phase, and the percent time spent in “off” phase exhibited a 30–40% reduction as compared to the pre-grafting values | [105]   |
| Dopamine neuron-contained tissue | PD              | Intracerebral           | Human embryonic mesencephalic tissue   | N/A         | 40                | 1 year                                            | human embryonic dopamine neuron transplants survive in patients with severe Parkinson’s disease and result in some clinical benefit in younger but not in older patients | [106]   |
| neuronal cells                | Stroke          | Intracerebral           | Human teratocarcinoma                 | N/A         | 12                | 18 months                                         | No adverse cell-related serologic or imaging-defined effects. The total European Stroke Scale score improved in six patients (3 to 10 points), with a mean improvement of 2.9 points in all patients | [107]   |

#### 3.5. Mesenchymal Stromal/Stem Cells (MSCs)

MSCs are multipotent cells that can differentiate into various cell types, including bone cells, muscle cells. In addition, it has been reported that MSCs can be transdifferentiated into neural cells under specific conditions, indicating the potential of MSCs for treating neurological diseases [49,108]. Human MSCs (hMSCs) can be easily obtained from many sources, among which the most studied hMSCs are those from bone marrow, umbilical cord, and adipose tissue. Although the detailed differences in their biological characteristics from different sources, the easy acquisition and the common properties, such as the capacity of self-renewing, multi-lineage differentiation, low tumorigenicity, low immunogenicity, and immunoregulatory function, have made hMSCs a promising candidate for cell therapy. Moreover, as mentioned above, hMSCs can also be a source of transplantable neural cells in vitro in models of neurological disorders.

Due to these advantages, hMSCs are currently one of the favorite cell types in cell therapy studies involving treating neurological diseases. Hundreds of animal studies have proved their safety and therapeutic effects for various neurological disorders (see Table S4). Moreover, even hMSC-conditioned medium or hMSCs-derived exosomes have been shown to alleviate the symptoms of experimental stroke or SCI [109,110]. Notably, although it has been reported that hMSCs can differentiate into neural cells in the injured area after transplantation [111,112], other researchers have also found that hMSCs could result in significant functional recovery without neural differentiation or even when hMSC is cleared away at the end of the experiment, suggesting that the main mechanisms of their beneficial functions are neurogenesis and angiogenesis promotion, anti-apoptosis, anti-inflammation, and immunomodulation rather than cell replacement [113–117]. Furthermore, studies have demonstrated that hMSCs can cross the blood-brain barrier (BBB) and home to the injured site through intravenous administration, which is a more suitable route for clinical use compared to direct local delivery to the affected tissue [118,119]. However, it is noteworthy that negative outcomes from hMSCs transplantation have also been shown in several studies, suggesting that administration of hMSCs alone may not be enough to generate significant therapeutic outcomes in some cases [120,121]. Therefore, several methods have been used to improve their therapeutic functions, such as pre-
treatment [122], genetic modification [123], co-transplantation with hNSPCs [63], combined with other treatments [124], and using biomaterial scaffolds as a carrier [125]. Interestingly, the therapeutic effects of hMSCs may also be related to the source of the cells or the age of the donor. Jumpei et al. have reported that human cranial bone-derived MSCs could result in significant functional recovery in a rat model of stroke, but not human iliac bone-derived MSCs [126]. Susumu et al. have reported that transplantation of hMSCs from young donors could provide better functional recovery through multiple mechanisms than old hMSCs [127].

To date, many clinical trials using umbilical cord-derived MSCs (UC-MSCs) or autologous bone marrow (BM-MSCs) or adipose-derived MSCs (hADSCs) for treating various neurological disorders have been conducted and published (see Table 5). However, most of the studies have only demonstrated the safety of hMSCs administration. Although the therapeutic effects have been seen in many clinical trials, the number of patients in each trial is usually not sufficient for analyzing the efficacy. Therefore, it is necessary to take hMSCs to the next step using more patients and proper controls to study their therapeutic effects and the mode of action in specific neurological disorders.

Table 5. Examples of hMSCs transplantation for neurological disorders in clinical trials (data from PubMed).

| Disease (Model) | Route of Administration | Cell Source | Cell Amount | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion | Ref. |
|-----------------|------------------------|-------------|-------------|-------------------|-----------------------------------------------|--------------------|-----|
| Cerebellar ataxia | Intrathecal | Bone marrow, (cell line: CS20BR08) | $2 \times 10^6$/kg | 1 | 10 months | No adverse events reported. Improved K-SARA (Korean version of the Scale for the Assessment and Rating of Ataxia) scores | [128] |
| ALS | Intrathecal | Autologous bone marrow | $30 \times 10^6$ | 8 | 14 months | No change in progression rate in patients with an inherently slow course, but some decreased progression rate in patients with an inherently rapid course | [129] |
| SCI | Intrathecal | Umbilical cord | $4 \times 10^6$/kg | 143 | 12 months | No serious adverse events reported. Significant improvements in neurological dysfunction and recovery of quality of life | [130] |
| Acute complete SCI | Intraspinal | Umbilical cord | 40 million | 40 | 12 months | Promoted recovery of neurological function | [131] |
| Chronic SCI | Intrathecal and intravenous | Autologous bone marrow | 6.6-7.6 $\times 10^7$ | 1 | 5 years | No complication or serious adverse effects, improved motoric function | [132] |
| Acute complete SCI | Intraspinal | Umbilical cord | $4 \times 10^7$ | 2 | 1 year | No obvious adverse symptoms reported, the supraspinal control of movements below the injury was regained by functional NeuroRegen scaffolds implantation with hMSCs | [133] |
| SCI | Intrathecal | Autologous adipose | $9 \times 10^7$ | 14 | 8 months | No serious adverse events. Several patients showed mild improvements in neurological function | [134] |
| | | Umbilical cord | $4.5-5.5 \times 10^7$ | 39 | 13 months | hMSCs transplantation was safe and effective at improving the gross motor and comprehensive function of children with cerebral palsy when combined with rehabilitation | [135] |
| Cerebral palsy | Intravenous | Umbilical cord | $8 \times 10^6$/kg | 1 | 18 months | No serious adverse effects reported. hMSCs transplantation improved functional recovery, combined with rehabilitation | [136] |
### Table 5. Cont.

| Disease (Model)       | Route of Administration | Cell Source                     | Cell Amount         | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion | Ref. |
|-----------------------|-------------------------|--------------------------------|---------------------|--------------------|---------------------------------------------------|--------------------|------|
| Cerebral palsy        | Intravenous             | Umbilical cord                 | $80 \times 10^7$   | 1                  | 5 years                                           | hMSCs transplantation with basic rehabilitation improved the motor and comprehensive function. No serious adverse events | [137] |
| TBI                   | Intrathecal, intramuscular, and intravenous | Wharton’s jelly | $18 \times 10^6 /\text{kg}$ | 1                  | 12 months                                         | No important negative effects were reported. The patients’ speech, cognitive, memory, and fine motor skills were improved | [138] |
| Chronic ischemic stroke | Intracerebral          | Bone marrow, cell line: SB623 | $2.5-10 \times 10^6$ | 18                 | 24 months                                         | All experienced at least 1 treatment-emergent adverse event. 7 experienced 9 serious adverse events, which resolved without sequelae. Improved clinical outcomes | [139] |
| Chronic stroke        | Intravenous             | Autologous bone marrow         | $5.3 \times 10^5$-2.9 $\times 10^6 /\text{kg}$ | 9                  | 60 weeks                                          | No adverse event reported. Improved neurological functions and clinical outcomes | [140] |
| Stroke                | Intravenous             | Autologous bone marrow         | 0.6 to $1.6 \times 10^6$ | 12                 | 12 months                                         | No significant adverse effects were found. Improved neurological function | [141] |
| HIE                   | Intrathecal, intramuscular, and intravenous | Wharton’s jelly | $12 \times 10^6 /\text{kg}$ | 1                  | 12 months                                         | Improved neurological recovery | [142] |
| HIE                   | Intravenous             | Umbilical cord                 | $1 \times 10^9$      | 22                 | 180 days                                          | No significant adverse effects were found. Markedly improved recovery of neurological function, cognition ability, emotional reaction, and extrapyramidal function | [143] |
| MS                    | Intravenous             | Umbilical cord                 | $14 \times 10^7$     | 20                 | 1 year                                            | No serious adverse events reported. Improved functional recovery | [144] |
| MS                    | Intravenous             | Autologous bone marrow         | 1–2 $\times 10^6 /\text{kg}$ | 24                 | 6 months                                          | No serious adverse effects reported. No substantial evidence of inhibition of disease activity, tissue repair, or recovery of function | [145] |
| MS                    | Intravenous             | Umbilical cord                 | $12 \times 10^6 /\text{kg}$ | 23                 | 12 months                                         | No significant adverse effects were found. Improved neurological function | [119] |
| Drug-resistant epilepsy | Intrathecal            | Autologous bone marrow         | $7.4-16 \times 10^7$ | 4                  | 2 years                                           | CD271+ hMSCs, combined with autologous bone marrow nucleated cells transplantation, showed no serious adverse events but considerable neurological and cognitive improvement | [146] |
| PD                    | Intracerebral           | Autologous bone marrow         | N/A                 | 7                  | 36 months                                         | No significant adverse effects were found. Several patients showed improved neurological function | [147] |

### 3.6. Dental Pulp Stem Cells (DPSCs) and Stem Cells from Human Exfoliated Deciduous Teeth (SHED)

DPSCs and SHED are derived from the dental pulp of adult permanent teeth and baby deciduous teeth, respectively. They are ectoderm-derived stem cells originating from neural crest cells and possess similar characteristics as MSCs, including the capacity of self-renew and multi-lineage differentiation and expression of MSC-related markers. However, it is still controversial to define DPSCs and SHED as MSCs, mainly due to their different potency of differentiating into specific lineages [148]. Because of their easy accessibility by routine dental procedures and their MSC-like properties, DPSCs and
SHED have gained more attention in the last decade in the field of regenerative medicine, including treating neurological diseases. Moreover, they can maintain their stemness and multipotency for many years by cryopreservation, therefore, providing an opportunity for cell banking [149,150].

Remarkably, it has been reported that, compared to BM-MSCs or hADSCs, DPSCs have a higher growth rate, stronger neurogenesis, and better neuro-supportive and neuro-protective properties in neurological injuries and pathologies [148], indicating they may have better therapeutic effects for neurological disorders. DPSCs have been used to treat many neurological disorders in animal studies and have led to significant beneficial outcomes (see Table S5), mainly through the secretion of neurotrophic factors and anti-inflammatory functions [151]. It has been reported that the expression of neurotrophic factors in DPSCs is higher than that of hADSCs and BM-MSCs [152]. The conditioned medium from DPSCs can also improve several neuropathological conditions, including ALS [151,153]. On the other hand, the therapeutic effects of SHED for neurological disorders have also been studied in some animal studies, which have shown improved results (see Table S5). It is suggested that SHED are in a more immature state than DPSCs with higher expression of pluripotent markers and a higher proliferation rate, while DPSCs show higher expression of neuroectodermal markers [154,155]. Similarly, the conditioned medium of SHED has also been proved to be therapeutic for animal model of stroke, PD, and TBI etc [156–158].

Overall, DPSCs and SHED are also promising candidates for treating neurological disorders and may be beyond hADSCs and BM-MSCs. However, due to the limited volume of the pulp tissue, it usually takes months to obtain enough cells for therapy from the primary isolation, although they have a high proliferation rate [148]. Moreover, the heterogeneity of DPSCs and SHED may affect their therapeutic potentials [159,160]. Moreover, most of the available evidence of their therapeutic function for neurological disorders was acquired using nonhuman xenotransplants. It is still a long way to study their therapeutic and side effects in humans.

3.7. Muse Cells

Muse cells (multilineage-differentiating stress enduring cells) are non-cancerous pluripotent stem cells that were first discovered by Yasumasa et al. in 2010 [161]. Muse cells are sporadically present in the connective tissue of nearly all organs, such as bone marrow and umbilical cord, and can even be collected from commercial cell lines, including human fibroblasts and bone marrow MSCs [161–163]. Interestingly, it has been reported that Muse cells are the primary source of hiPSCs in human fibroblasts, but not the non-Muse cells [164,165]. Moreover, as Muse cells are present in cultured MSCs, it is thought that Muse cells are more therapeutic in clinical MSCs therapies regarding tissue regeneration [166]. The characteristics of Muse cells, including non-tumorigenicity, pluripotency, and easy collection, have made Muse cells a promising candidate for cell therapy.

Several animal studies have shown the safety and effectiveness of human Muse cells for treating neurological disorders, such as stroke, intracerebral hemorrhage, encephalopathy, ALS, and SCI (see Table S6). Moreover, Muse cells can engraft and integrate into the damaged regions and differentiate into neuronal cells, and finally, lead to functional and morphological recovery after intravenous administration [167–170]. However, Muse cells are still a novel type of stem cells that have not been well studied as other stem cells. With more related studies, we will obtain a better understanding of Muse cells and their potentials for treating neurological disorders.

3.8. Olfactory Ensheathing Cells (OECs)

OECs, also known as olfactory ensheathing glia, are terminally differentiated and self-renewable cells that are found in both the peripheral nervous system (PNS) and CNS, supporting the regeneration of the olfactory system throughout life. OECs can be isolated from the olfactory bulb (OB-OECs) through intracranial surgery or from olfactory mucosa
(OM-OECs) through a simple, non-invasive nasal biopsy, which is preferred for autologous transplantation. Based on these properties, human OECs (hOECs) are considered a suitable candidate for CNS transplantation, particularly for SCI treatment. Numerous animal studies have shown that hOECs could promote the recovery from SCI through various mechanisms, including neuroprotection, promoting axonal growth/sprouting, improving angiogenesis, and restriction of glial scar [171,172]. Notably, OECs from different sites may act through different mechanisms. It has been reported that OM-OECs could regulate extracellular matrix and improve angiogenesis, while OB-OECs intend to improve axonal regeneration [172]. In addition to the animal studies, hOECs have also been used in clinical trials for SCI since the early 2000s (see Table 6). Although with a relatively small size of patients and variable outcomes in different patients, hOECs transplantation has led to different levels of functional recovery in most cases, indicating their therapeutic roles for SCI. Moreover, hOECs have also been used for treating ALS and cerebral palsy patients and have resulted in functional improvements, suggesting their therapeutic potentials are not only for SCI but also for other neurological disorders [173,174].

However, several bottlenecks are impeding the therapeutic effects of hOECs. hOECs isolated from the olfactory bulb or olfactory mucosa usually contain contamination cells such as fibroblasts that may affect their effects and need to be purified [175–177]. Moreover, the difficulty to quickly expand, poor survival after suspension injection, limited migration, and phagocytosis are also considered the major hampers of hOECs treatments [175]. Although various methods have been used to optimize OECs transplantation, it is still far from being a mature treatment for neurological disorders, including SCI [175].

Table 6. Examples of OECs transplantation for neurological disorders in clinical trials (data from PubMed).

| Disease | Route of Administration | Cell Source | Cell Amount | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion (Targeting Behavioral and Histological Change) | Ref. |
|---------|------------------------|-------------|-------------|-------------------|-----------------------------------------------|---------------------------------------------------------------|------|
| SCI     | Intraspinal            | Autologous olfactory bulb | $5 \times 10^5$ | 1                 | 19 months                                     | Improved neurological and histopathological recovery, no adverse effects were seen | [178] |
| SCI     | Intraspinal            | Human fetal olfactory bulbs | $1 \times 10^5$ | 7                 | 6 months                                      | No serious adverse effects were seen. All treated patients showed functional improvement, 4/5 showed improvement in electrophysiological tests | [177] |
| SCI     | Intraspinal            | Human fetal olfactory bulbs | $2-5 \times 10^6$ | 15                | 8 weeks                                       | No serious adverse effects were seen. 12/15 showed obvious spinal function improvement, and 3/15 had slight improvement | [179] |
| SCI     | Intraspinal            | Autologous nasal mucosa | 1.8–21.2 × 10⁶ | 6                 | 1 year                                        | No adverse findings related to olfactory mucosa biopsy or transplantation. All treated patients showed improved functional recovery; 2/3 of treated patients showed improved American Spinal Injury Association class | [176] |
| SCI     | Intraspinal            | Human fetal olfactory bulbs | $2 \times 10^5$ | 6                 | 24 months                                     | No clinical complications were observed. All patients showed improved neurofunctional recovery | [180] |
| SCI     | Intraspinal            | Autologous olfactory mucosa | Not mentioned | 8                 | 24 months                                     | No clinical complications were observed. All patients showed improved neurofunctional recovery; 3/8 showed returned substantial sensation and motor activity in various muscles, 2/8 showed restored bladder function | [181] |
Table 6. Cont.

| Disease      | Route of Administration | Cell Source               | Cell Amount | Number of Patients | Longest Follow-Up Time (after 1st Transplantation) | Outcome/Conclusion               | Ref.          |
|--------------|-------------------------|---------------------------|-------------|-------------------|-----------------------------------------------------|---------------------------------|--------------|
| SCI          | Intraspinal             | Human fetal olfactory bulbs | $5 \times 10^5$ | 11     | 1.5 years       | All patients had no complications or deterioration of neurological conditions. Sensation and spasticity improved moderately. Locomotion recovery was minimal | [182]        |
| SCI          | Intraspinal             | olfactory bulbs           | $5 \times 10^5$ | 108    | 5.3 years       | No serious adverse effects were seen. Improve neurological functions. Sufficient rehabilitation most likely played a critical role | [183]        |
| SCI          | Intraspinal             | olfactory bulbs           | $5 \times 10^5$ | 171    | 12 weeks        | OECs transplantation can improve the neurological function of spinal cord of SCI patients regardless of their ages | [184]        |
| ALS          | Intracranial and/or intraspinal | Human fetal olfactory bulbs | $1-2 \times 10^6$/treatment, 1–5 treatments | 507    | N/A            | multiple doses of cellular therapy serve a positive role in the treatment of ALS | [173]        |
| Cerebral palsy | Intracranial             | Human fetal olfactory bulbs | $2 \times 10^6$ | 14     | 6 months        | OECs transplantation is effective for functional improvement in children and adolescents with cerebral palsy, yet without obvious side effects | [174]        |

3.9. Hematopoietic Stem Cells (HSCs)

HSCs are multipotent cells that generate all types of blood cells and can be found in peripheral blood, bone marrow (which provides an opportunity for autologous transplantation), and umbilical cord blood. Human HSCs (hHSCs) are one of the earliest cell types that have been used for clinical transplantation for the treatment of certain cancerous diseases, with acceptable safety [185]. Due to their ability to generate new blood and immune cells, hHSCs, especially autologous hHSCs, have also been used to treat autoimmune diseases of the nervous system, including MS, in the last two decades [186]. Currently, thousands of MS patients have been treated with autologous hHSCs, and many of them have shown significant therapeutic outcomes. However, in comparison to other stem cells, hHSCs only work as a supportive blood product following chemotherapy to speed hematopoietic recovery rather than a single treatment for these diseases. Actually, “autologous hematopoietic stem cell transplantation (AH SCT)” has become a clinical term that contains several procedures, including (1) mobilization—releasing hHSCs from the bone marrow into peripheral blood, (2) harvesting—collecting hHSCs from the blood of the patient, (3) conditioning regimen—administration of cytotoxic chemotherapy, and (4) infusion—returning hHSCs to the patient by infusion into the veins. Overall, with more clinical experience, AH SCT has become a promising supportive strategy for treating MS. The current status of using AH SCT for MS is well reviewed in a published paper [187].

4. Discussion

Cell therapy for neurological disorders has attracted more and more attention from researchers due to its unique and promising therapeutic potentials through the capabilities of cell replacement, neuroprotection, and promotion of intrinsic neuro-restoration. In this paper, we have introduced some promising cell types and their applications in treating neurological disorders both in animal studies and clinical trials. As we have summarized (see Table 7), each type of cell has its unique properties and may have different therapeutic functions in treating different diseases. However, it is worth mentioning that, although we have listed some common neurological disorders, the potential targets of the cells are not limited to what we have mentioned above. For example, MSCs have also been shown to be therapeutic for autism and meningitis, etc. [188,189]. An ideal cell type is not only
about its therapeutic effects but also about its accessibility and cost and the time to obtain sufficient quantities. Therefore, it is hard to identify the best cell candidate for neurological disorders at the current stage without enough comparative data.

**Table 7. Characteristics of cell candidates for neurological disorders through direct transplantation.**

| Cell Type | Stemness | Advantage                                                                 | Disadvantage                                                                                                                                                                                                 | Examples of Targeted Neurological Disorders in Animal Studies | Examples of Targeted Neurological Disorders in Clinical Trials |
|-----------|----------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|
| hESCs     | Pluripotent | Unlimited proliferation, unlimited differentiation, high accessibility     | Ethical issues; risk of immune rejection, risk of tumor formation                                                                                                                                              | SCI                                                          | Lyme disease, MS, SCI, stroke, cerebral palsy               |
| hiPSCs    | Pluripotent | No ethical issues; applicable for autologous transplantation; high accessibility | Risk of tumor formation, unpredictable mutagenesis                                                                                                                                                          | SCI, stroke                                                  | N/A                                                         |
| hNSPCs    | Multipotent | Neural lineage differentiation, low risk of tumor formation, multiple sources | Comparatively low proliferation                                                                                                                                                                             | SCI, HD, stroke, PD, AD, ataxia, TBI, ALS                    | Stroke, ALS, PD, SCI, MS, TBI, cerebral palsy               |
| Neurons   | Terminal cells | No risk of tumor formation, no unexpected differentiation              | Poor survival after transplantation                                                                                                                                                                          | SCI, ALS, PD, AD                                            | PD, stroke                                                  |
| Oligodendrocytes | Terminal cells | No risk of tumor formation, no unexpected differentiation | Poor survival after transplantation                                                                                                                                                                          | MS, SCI                                                     | N/A                                                         |
| Astrocytes | Terminal cells | No risk of tumor formation, no unexpected differentiation | Effects highly depend on the subtype of the cells, not much studied                                                                                                                                            | SCI                                                         | N/A                                                         |
| hMSCs     | Multipotent | Applicable for autologous transplantation; high accessibility, low risk of tumor formation | Limited neural differentiation; effects may not be as suitable as hNSPCs                                                                                                                                 | SCI, PD, stroke, TBI, ALS, ataxia, MS, AD, epilepsy          | SCI, PD, stroke, TBI, ALS, ataxia, MS, epilepsy, cerebral palsy, HIE |
| DPSCs     | Multipotent | Applicable for autologous transplantation; high accessibility, low risk of tumor formation | Limited neural differentiation, high heterogeneity; low number of cells from pulp tissue                                                                                                                                 | SCI, HD, ataxia, stroke, PD                                 | N/A                                                         |
| SHED      | Multipotent | High accessibility, low risk of tumor formation                           | Limited neural differentiation, high heterogeneity; low number of cells from pulp tissue                                                                                                                                 | SCI, stroke                                                  | N/A                                                         |
| Muse cells | Pluripotent | Applicable for autologous transplantation; high accessibility, non-tumorigenicity | Not much studied                                                                                                                                                                                              | SCI, stroke, HIE, ALS                                        | N/A                                                         |
| hOECs     | Terminal cells | Applicable for autologous transplantation; high accessibility, non- tumorigenicity, no unexpected differentiation | Hard to purify; poor survival after transplantation; limited migration and phagocytosis;                                                                                                                                 | SCI                                                         | SCI, ALS, cerebral palsy                                   |
| hHSCs     | Multipotent | Applicable for autologous transplantation; high accessibility             | Some risk of serious adverse effects                                                                                                                                                                          | N/A                                                         | MS                                                          |

Abbreviation: SCI = spinal cord injury; MS = multiple sclerosis; HD = Huntington’s disease; TBI = traumatic brain injury; PD = Parkinson’s disease; AD = Alzheimer’s disease; ALS = amyotrophic lateral sclerosis; HIE = hypoxic-ischemic encephalopathy; N/A = not applicable.

Aside from cell type, cell source, and the target disease, the outcome of cell therapy can also be highly influenced by other factors, including the route and cell quantity of cell administration. Intracerebral and intraspinal administration can bring more cells to the target position but may cause unexpected adverse effects due to the procedure, while intravenous or intranasal injections are safer but may lead to a loss of the cells. In addition, a successful cell therapy usually needs millions of cells for transplantation to humans; however, the cells are not “the more, the better” as more cells may result in negative outcomes, for example, reducing the safety of the cell therapy. Therefore, a proper delivery approach and a safe and therapeutic range of the quantity of the cells need to be found for specific diseases in future studies. Luckily, despite being at the pre-clinical stage of development, several methods have been proven to improve the therapeutic effects of the cells, such as genetic modification, pre-conditioning, and co-transplantation. With more studies conducted, it is possible to develop more effective cell therapies for patients with neurological disorders.
However, it is noteworthy that although animal studies usually show significant improvement after cell transplantation, the outcomes from clinical trials are normally not as suitable as from animal studies due to the differences between clinical diseases and animal models, such as the far greater heterogeneity between human patients than that of purpose-bred animals. Therefore, some success in animal studies may not be transferred to human studies, indicating the need to build up more clinically related animal models.

5. Conclusions

In this paper, we have introduced some promising cells that may be clinically therapeutic for the treatment of neurological disorders, based on their characteristics and the results from related clinical trials and recent animal studies. Overall, with more knowledge about these cells, it can be foreseen that cell therapy will have a crucial place in the future clinical management of neurological disorders, although there is still much work that remains to be done.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.390/biology10111142/s1, Table S1: Examples of hiPSC transplantation for neurological disorders in animal studies since 2016 (data from PubMed). Table S2: Examples of hNSPC transplantation for neurological disorders in animal studies since 2016 (data from PubMed). Table S3: Examples of human neuron, oligodendrocyte, and astrocyte transplantation for neurological disorders in animal studies since 2016 (data from PubMed). Table S4: Examples of hMSC transplantation for neurological disorders in animal studies since 2016 (data from PubMed). Table S5: Examples of DPSC and SHED transplantation for neurological disorders in animal studies since 2016 (data from PubMed). Table S6: Examples of human Muse cell transplantation for neurological disorders in animal studies since 2016 (data from PubMed).

Author Contributions: All authors contributed to the idea for this article. D.L. performed the literature search and original draft preparation. L.B. and X.-F.Z. critically revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Acknowledgments: We would like to thank the University of South Australia and the China Scholarship Council for their support throughout this work.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Muthuraman, M.; Koirala, N.; Ciolac, D.; Pintea, B.; Glaser, M.; Groppa, S.; Tamas, G.; Groppa, S. Deep brain stimulation and l-dopa therapy: Concepts of action and clinical applications in Parkinson’s disease. Front. Neurol. 2018, 9, 711. [CrossRef] [PubMed]
2. Matsunaga, S.; Kishi, T.; Iwata, N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: A systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 2014, 18, P859–P860. [CrossRef]
3. Besusso, D.; Schellino, R.; Boido, M.; Belloli, S.; Parolisi, R.; Conforti, P.; Faedo, A.; Cernigoj, M.; Campus, I.; Laporta, A.; et al. Stem cell-derived human striatal progenitors innervate striatal targets and alleviate sensorimotor deficit in a rat model of Huntington disease. Stem Cell Rep. 2020, 14, 876–891. [CrossRef] [PubMed]
4. Marques, C.R.; Marote, A.; Mendes-Pinheiro, B.; Teixeira, F.G.; Salgado, A.J. Cell secretome based approaches in Parkinson’s disease regenerative medicine. Expert Opin. Biol. Ther. 2018, 18, 1235–1245. [CrossRef]
5. Bellak, T.; Fekacs, Z.; Torok, D.; Tancos, Z.; Nemes, C.; Teszla, Z.; Gal, L.; Polgari, S.; Kobolak, J.; Dinnyes, A.; et al. Grafted human induced pluripotent stem cells improve the outcome of spinal cord injury: Modulation of the lesion microenvironment. Sci. Rep. 2020, 10, 22414. [CrossRef]
6. Mason, C.; Dunnill, P. Assessing the value of autologous and allogeneic cells for regenerative medicine. Regen. Med. 2009, 4, 835–853. [CrossRef] [PubMed]
7. Shroff, G. A review on stem cell therapy for multiple sclerosis: Special focus on human embryonic stem cells. Stem Cells Cloning 2018, 11, 1–11. [CrossRef] [PubMed]
8. De Gioia, R.; Biella, F.; Citterio, G.; Rizzo, F.; Abati, E.; Nizzardo, M.; Bresolin, N.; Comi, G.P.; Corti, S. Neural stem cell transplantation for neurodegenerative diseases. Int. J. Mol. Sci. 2020, 21, 3103. [CrossRef] [PubMed]
9. Zhou, T.; Benda, C.; Dunzinger, S.; Huang, Y.; Ho, J.C.; Yang, J.; Wang, Y.; Zhang, Y.; Zhuang, Q.; Li, Y.; et al. Generation of human induced pluripotent stem cells from urine samples. *Nat. Protoc.* 2012, 7, 2080–2089. [CrossRef] [PubMed]

10. Capetian, P.; Azmitia, L.; Pauly, M.G.; Krajka, V.; Stengel, F.; Bernhardi, E.M.; Klett, M.; Meier, B.; Seibler, P.; Stanslowsky, N.; et al. Plasmid-based generation of induced neural stem cells from adult human fibroblasts. *Front. Cell Neurosci.* 2016, 10, 245. [CrossRef] [PubMed]

11. Augustyniak, J.; Zychowicz, M.; Podobinska, M.; Barta, T.; Buzanska, L. Reprogramming of somatic cells: Possible methods to derive safe, clinical-grade human induced pluripotent stem cells. *Acta Neurobiol. Exp.* 2014, 74, 373–382.

12. Ebrahimi, A.; Keske, E.; Mehdirapor, A.; Ebrahimi-Kalan, A.; Ghorbani, M. Somatic cell reprogramming as a tool for neurodegenerative diseases. *Biomed. Pharmacother.* 2019, 112, 108663. [CrossRef] [PubMed]

13. Zhou, J.; Sun, J. A revolution in reprogramming: Small molecules. *Curr. Mol. Med.* 2019, 19, 77–90. [CrossRef] [PubMed]

14. Yang, W.Z.; Zhang, Y.; Wu, F.; Min, W.P.; Minev, B.; Zhang, M.; Luo, X.L.; Ramos, F.; Ichim, T.E.; Riordan, N.H.; et al. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. *J. Transl. Med.* 2010, 8, 75. [CrossRef] [PubMed]

15. Lin, C.S.; Lin, G.; Lue, T.F. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. *Stem Cells Dev.* 2012, 21, 2770–2778. [CrossRef]

16. Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; Waknitz, M.A.; Swiergiel, J.J.; Marshall, V.S.; Jones, J.M. Embryonic stem cell lines derived from human blastocysts. *Science* 1998, 282, 1145–1147. [CrossRef] [PubMed]

17. McDonald, J.W.; Liu, X.Z.; Qu, Y.; Liu, S.; Mickey, S.K.; Turetsky, D.; Gottlieb, D.I.; Choi, D.W. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. *Nat. Med.* 1999, 5, 1410–1412. [CrossRef] [PubMed]

18. Srivastava, A.S.; Shenouda, S.; Mishra, R.; Carrier, E. Transplanted embryonic stem cells successfully survive, proliferate, and migrate to damaged regions of the mouse brain. *Stem Cells* 2006, 24, 1689–1694. [CrossRef] [PubMed]

19. Liu, X.; Li, W.; Fu, X.; Xu, Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. *Front. Immunol.* 2017, 8, 645. [CrossRef]

20. Hentze, H.; Soong, P.L.; Wang, S.T.; Phillips, B.W.; Putti, T.C.; Dunn, N.R. Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies. *Stem Cell Res.* 2009, 2, 198–210. [CrossRef] [PubMed]

21. Lee, A.S.; Tang, C.; Rao, M.S.; Weissman, I.L.; Wu, J.C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. *Nat. Med.* 2013, 19, 998–1004. [CrossRef] [PubMed]

22. Acquarone, M.; de Melo, T.M.; Meireles, F.; Brito-Moreira, J.; Oliveira, G.; Ferreira, S.T.; Castro, N.G.; Tovar-Moll, F.; Houzel, J.C.; Rehen, S.K. Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of parkinson’s disease. *Front. Cell Neurosci.* 2015, 9, 97. [CrossRef] [PubMed]

23. Matsuda, R.; Yoshikawa, M.; Kimura, H.; Ouji, Y.; Nakase, H.; Nishimura, F.; Nonaka, J.; Toriumi, H.; Yamada, S.; Nishiofuku, M.; et al. Cotransplantation of mouse embryonic stem cells and bone marrow stromal cells following spinal cord injury suppresses tumor development. *Cell Transpl.* 2009, 18, 39–54. [CrossRef] [PubMed]

24. Erceg, S.; Ronagh, M.; Oria, M.; Rosello, M.G.; Arago, M.A.; Lopez, M.G.; Radojevic, I.; Moreno-Manzano, V.; Rodriguez-Jimenez, F.J.; Chattahcharya, S.S.; et al. Transplanted oligodendrocytes and motoneuron progenitors generated from human embryonic stem cells promote locomotor recovery after spinal cord transaction. *Stem Cells* 2010, 28, 1541–1549. [CrossRef] [PubMed]

25. Qiu, X.; Liu, Y.; Xiao, X.; He, J.; Zhang, H.; Li, Y. In vitro induction of human embryonic stem cells into the midbrain dopaminergic neurons and transplantation in cynomolgus monkey. *Cell Reprogram.* 2019, 21, 285–295. [CrossRef] [PubMed]

26. de Castro, M.V.; da Silva, M.V.R.; Chiarotto, G.B.; Santana, M.H.A.; Luzzo, A.C.M.; Kyrylenko, S.; de Oliveira, A.L.R. Spinal reflex recovery after dorsal rhizotomy and repair with platelet-rich plasma (ppr) gel combined with bioengineered human embryonic stem cells (hescs). *Stem Cells Int.* 2020, 2020, 8834360. [CrossRef] [PubMed]

27. Shroff, G. Evaluation of patients with multiple sclerosis using reverse nutech functional score and expanded disability status scale after human embryonic stem cell therapy. *Clin. Transl. Cell Med.* 2016, 5, 43, Erratum in 2017, 6, 35. [CrossRef] [PubMed]

28. Shroff, G.; Thakur, D.; Dhingra, V.; Baroli, D.S.; Khatri, D.; Gautam, R.D. Expression of concern to: Role of physiotherapy in the mobilization of patients with spinal cord injury undergoing human embryonic stem cells transplantation. *Clin. Transl. Med.* 2017, 6, 35. [CrossRef] [PubMed]

29. Shroff, G. Single-photon emission tomography imaging in patients with lyme disease treated with human embryonic stem cells. *Neuroradiol. J.* 2018, 31, 157–167. [CrossRef] [PubMed]

30. Shroff, G. Transplantation of human embryonic stem cells in patients with multiple sclerosis and lyme disease. *Am. J. Case Rep.* 2016, 17, 944–949. [CrossRef] [PubMed]

31. Shroff, G.; Gupta, R. Human embryonic stem cells in the treatment of patients with spinal cord injury. *Ann. Neurosci.* 2015, 22, 208–216. [CrossRef] [PubMed]

32. Shroff, G. Human embryonic stem cell therapy in chronic spinal cord injury: A retrospective study. *Clin. Transl. Sci.* 2016, 9, 168–175. [CrossRef] [PubMed]

33. Shroff, G. Comparison of nutech functional score with european stroke scale for patients with cerebrovascular accident treated with human embryonic stem cells: Nfs for cva patients treated with hescs. *J. Vasc. Interv. Neurol.* 2017, 9, 35–43. [PubMed]

34. Shroff, G.; Gupta, A.; Barthakur, J.K. Therapeutic potential of human embryonic stem cell transplantation in patients with cerebral palsy. *J. Transl. Med.* 2014, 12, 318. [CrossRef] [PubMed]
35. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [CrossRef]

36. Warren, L.; Manos, P.D.; Ahfeldt, T.; Loh, Y.H.; Li, H.; Lau, F.; Ebina, W.; Mandal, P.K.; Smith, Z.D.; Meissner, A.; et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mrna. Cell Stem Cell 2010, 7, 618–630. [CrossRef]

37. Okita, K.; Matsumura, Y.; Sato, Y.; Okada, A.; Morizane, A.; Okamoto, S.; Hong, H.; Nakagawa, M.; Tanabe, K.; Tezuka, K.; et al. A more efficient method to generate integration-free human iips cells. Nat. Methods 2011, 8, 409–412. [CrossRef] [PubMed]

38. Yu, J.; Chau, K.F.; Vodyanik, M.A.; Jiang, J.; Jiang, Y. Efficient feeder-free episomal reprogramming with small molecules. PLoS ONE 2011, 6, e17557. [CrossRef]

39. Cherkashova, E.A.; Leonov, G.E.; Namestnikova, D.D.; Solov’eva, A.A.; Gubskii, I.L.; Bukharova, T.B.; Gubskii, L.V.; Goldenstein, D.V.; Yarygin, K.N. Methods of generation of induced pluripotent stem cells and their application for the therapy of central nervous system diseases. Bull. Exp. Biol. Med. 2020, 168, 566–573. [CrossRef] [PubMed]

40. Qin, J.; Gong, G.M.; Sun, S.L.; Qi, J.; Zhang, H.L.; Wang, Y.L.; Wang, N.; Wang, Q.M.; Ji, Y.; Gao, Y.; et al. Functional recovery after transplantation of induced pluripotent stem cells in a rat hemorrhagic stroke model. Neurosci. Lett. 2013, 554, 70–75. [CrossRef] [PubMed]

41. Chang, D.J.; Lee, N.; Park, I.H.; Choi, C.; Jeon, I.; Kwon, J.; Oh, S.H.; Shin, D.A.; Do, J.T.; Lee, D.R.; et al. Therapeutic potential of human induced pluripotent stem cells in experimental stroke. Cell Transpl. 2013, 22, 1427–1440. [CrossRef]

42. Palma-Tortosa, S.; Tornero, D.; Gronning Hansen, M.; Monni, E.; Hajy, M.; Kartsivadse, V.; Aktay, S.; Tsupsykov, O.; Parmar, M.; Deisseroth, K.; et al. Activity in grafted human ips cell-derived cortical neurons integrated in stroke-injured rat brain regulates motor behavior. Proc. Natl. Acad. Sci. USA 2011, 108, 9094–9100. [CrossRef]

43. Chen, K.H.; Lin, K.C.; Wallace, C.G.; Li, Y.C.; Shao, P.L.; Shao, Y.J.; Sung, P.H.; Yip, H.K. Human induced pluripotent stem cell-derived mesenchymal stem cell therapy effectively reduced brain infarct volume and preserved neurological function in rat after acute intracranial hemorrhage. Am. J. Transl. Res. 2019, 11, 6232–6248. [PubMed]

44. Takahashi, J. Ips cell-based therapy for parkinson’s disease: A kyoto trial. Regen. Ther. 2020, 13, 18–22. [CrossRef] [PubMed]

45. Tsuji, O.; Sugai, K.; Yamaguchi, R.; Tashiro, S.; Nagoshi, N.; Kohyama, J.; Iida, T.; Ohkubo, T.; Itakura, G.; Isoda, M.; et al. Concise review: Laying the groundwork for a first-in-human study of an induced pluripotent stem cell-based cell therapy trials for spinal cord injury. Stem Cells 2019, 37, 6–13. [CrossRef]

46. Okubo, T.; Iwanami, A.; Kohyama, J.; Itakura, G.; Kawabata, S.; Nishiyama, Y.; Sugai, K.; Ozaki, M.; Iida, T.; Matsubayashi, K.; et al. Pretreatment with a gamma-secretase inhibitor prevents tumor-like overgrowth in human ipsc-derived transplants for spinal cord injury. Stem Cell Rep. 2016, 7, 649–663. [PubMed]

47. Ming, G.L.; Song, H. Adult neurogenesis in the mammalian central nervous system. Annu. Rev. Neurosci. 2005, 28, 223–250. [CrossRef]

48. Kuhn, H.G.; Dickinson-Anson, H.; Gage, F.H. Neurogenesis in the dentate gyrus of the adult rat: Age-related decrease of neuronal progenitor proliferation. J. Neurosci. 1996, 16, 2027–2033. [CrossRef] [PubMed]

49. Alexanian, A.R. An efficient method for generation of neural-like cells from adult human bone marrow-derived mesenchymal stem cells. Regen. Med. 2010, 5, 891–900. [CrossRef]

50. Kim, H.W.; Lee, H.S.; Kang, J.M.; Bae, S.H.; Kim, C.; Lee, S.H.; Schwarz, J.; Kim, G.J.; Kim, J.S.; Cha, D.H.; et al. Dual effects of human placenta-derived neural cells on neuroprotection and the inhibition of neuroinflammation in a rodent model of parkinson’s disease. Cell Transpl. 2018, 27, 814–830. [CrossRef]

51. Zou, Y.; Zhao, Y.; Xiao, Z.; Chen, B.; Ma, D.; Shen, H.; Gu, R.; Dai, J. Comparison of regenerative effects of transplanting three-dimensional longitudinal scaffold-loaded human mesenchymal stem cells and human neural stem cells on spinal cord completely transected rats. ACS Biomater. Sci. Eng. 2020, 6, 1671–1680. [CrossRef]

52. Lin, G.Q.; He, X.F.; Liang, F.Y.; Guo, Y.; Sunناسee, G.; Chen, J.; Cao, X.M.; Chen, Y.Y.; Pan, G.J.; Pei, Z.; et al. Transplanted human neural precursor cells integrate into the host neural circuit and ameliorate neurological deficits in a mouse model of traumatic brain injury. Neurosci. Lett. 2018, 674, 11–17. [CrossRef] [PubMed]

53. Lu, M.H.; Ji, W.L.; Chen, H.; Sun, Y.Y.; Zhao, X.Y.; Wang, F.; Shi, Y.; Hu, Y.N.; Liu, B.X.; Wu, J.W.; et al. Intranasal transplantation of human neural stem cells ameliorates Alzheimer’s disease-like pathology in a mouse model. Front. Aging Neurosci. 2021, 13, 10151. [CrossRef]

54. Lee, I.S.; Jung, K.; Kim, I.S.; Lee, H.; Kim, M.; Yun, S.; Hwang, K.; Shin, J.E.; Park, K.I. Human neural stem cells alleviate alzheimer-like pathology in a mouse model. Mol. Neurodegener. 2015, 10, 38. [CrossRef]

55. Liu, A.M.; Kang, S.; Yu, P.P.; Shi, L.L.; Zhou, L.B. Transplantation of human urine-derived neural progenitor cells after spinal cord injury in rats. Neurosci. Lett. 2020, 735, 135201. [CrossRef] [PubMed]

56. Mendes-Pinheiro, B.; Teixeira, F.G.; Anjo, S.I.; Manadas, B.; Behie, L.A.; Salgado, A.J. Secretome of undifferentiated neural progenitor cells induces histological and motor improvements in a rat model of parkinson’s disease. Stem Cell Transl. Med. 2018, 7, 829–838. [CrossRef] [PubMed]

57. Kim, H.S.; Jeon, J.; Noh, J.E.; Lee, H.; Hong, K.S.; Lee, N.; Pei, Z.; Song, J. Intracerebral transplantation of bdnf-overexpressing human neural stem cells (hb1.F3.Bdnf) promotes migration, differentiation and functional recovery in a rodent model of huntington’s disease. Exp. Neurol. 2020, 290, 130–137. [CrossRef] [PubMed]
58. Thomsen, G.M.; Avalos, P.; Ma, A.A.; Alkaslasi, M.; Cho, N.; Wyss, L.; Vit, J.P.; Godoy, M.; Suezaki, P.; Shelest, O.; et al. Transplantation of neural progenitor cells expressing glial cell line-derived neurotrophic factor into the motor cortex as a strategy to treat amyotrophic lateral sclerosis. Stem Cells 2018, 36, 1122–1131. [CrossRef]
59. McGinley, J.L.; Kashlan, O.N.; Bruno, E.S.; Chen, K.S.; Hayes, J.M.; Kashlan, S.R.; Raykin, J.; Johe, K.; Murphy, G.G.; Feldman, E.L. Human neural stem cell transplantation improves cognition in a murine model of Alzheimer’s disease. Sci. Rep. 2018, 8, 14776. [CrossRef]
60. Okubo, T.; Nagoshi, N.; Kohyama, J.; Tsuji, O.; Shinozaki, M.; Shibata, S.; Kase, Y.; Matsumoto, M.; Nakamura, M.; Okano, H. Treatment with a gamma-secretase inhibitor promotes functional recovery in human ipsc-derived transplants for chronic spinal cord injury. Stem Cell Rep. 2018, 11, 1416–1432. [CrossRef]
61. Ould-Brahim, F.; Sarma, S.N.; Syal, C.; Lu, K.J.; Seegobin, M.; Carter, A.; Jeffers, M.S.; Dor, C.; Stanford, W.L.; Corbett, D.; et al. Metformin preconditioning of human induced pluripotent stem cell-derived neural stem cells promotes their engraftment and improves post-stroke regeneration and recovery. Stem Cells Dev. 2018, 27, 1085–1096. [CrossRef]
62. Kim, M.; Jung, K.; Ko, Y.; Kim, I.S.; Hwang, K.; Jang, J.H.; Shin, J.E.; Park, K.I. Tnf-alpha pretreatment improves the survival and function of transplanted human neural progenitor cells following hypoxic-ischemic brain injury. Cells 2020, 9, 1195. [CrossRef] [PubMed]
63. Sun, L.; Wang, F.; Chen, H.; Liu, D.; Qu, T.; Li, X.; Xu, D.; Liu, F.; Yin, Z.; Chen, Y. Co-transplantation of human umbilical cord mesenchymal stem cells and human neural stem cells improves the outcome in rats with spinal cord injury. Cell Transpl. 2019, 28, 893–906. [CrossRef]
64. Zou, Y.L.; Ma, D.Z.; Shen, H.; Zhao, Y.N.; Xu, B.; Fan, Y.H.; Sun, Z.; Chen, B.; Xue, W.W.; Shi, Y.; et al. Aligned collagen scaffold combination with human spinal cord-derived neural stem cells to improve spinal cord injury repair. Biomater. Sci. 2020, 8, 5145–5156. [CrossRef]
65. Abdolahi, S.; Aligholi, H.; Khodakaram-Tafti, A.; Ghadiri, M.K.; Stummer, W.; Gorji, A. Improvement of rat spinal cord injury following lentiviral vector-transduced neural stem/progenitor cells derived from human epileptic brain tissue transplantation with a self-assembling peptide scaffold. Mol. Neurobiol. 2021, 58, 2481–2493. [CrossRef]
66. Kajikawa, K.; Imaizumi, K.; Shinozaki, M.; Shibata, S.; Shindo, T.; Kitagawa, T.; Shibata, R.; Kamata, Y.; Kojima, K.; Nagoshi, N.; et al. Cell therapy for spinal cord injury by using human ipsc-derived region-specific neural progenitor cells. Mol. Brain 2020, 13, 120. [CrossRef] [PubMed]
67. Feldman, E.L.; Boulis, N.M.; Hur, J.; Johe, K.; Rutkove, S.B.; Federici, T.; Polak, M.; Bordeau, J.; Sakowski, S.A.; Glass, J.D. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes. Ann. Neurol. 2014, 75, 363–373. [CrossRef]
68. Curtis, E.; Martin, J.R.; Gabel, B.; Sidhu, N.; Rzesiewicz, T.K.; Mandeville, R.; Van Gorp, S.; Leerink, M.; Tadokoro, T.; Marsala, S.; et al. A first-in-human, phase i study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell 2018, 22, 941–950. [CrossRef] [PubMed]
69. Zhang, G.Z.; Li, Y.; Reuss, J.L.; Liu, N.; Wu, C.Y.; Li, J.P.; Xu, S.S.; Wang, F.; Hazel, T.G.; Cunningham, M.; et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke. Stem Cell Transl. Med. 2019, 8, 999–1007. [CrossRef]
70. Chen, G.J.; Wang, Y.L.; Xu, Z.Y.; Fang, F.; Xu, R.M.; Wang, Y.; Hu, X.L.; Fan, L.X.; Liu, H.Q. Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy. J. Transl. Med. 2013, 11, 21. [CrossRef] [PubMed]
71. Harris, V.K.; Vyshkina, T.; Sadiq, S.A. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Mol. Neurobiol. 2016, 18, 1476–1482. [CrossRef]
72. Wang, Z.G.; Luo, Y.; Chen, L.A.; Liang, W. Safety of neural stem cell transplantation in patients with severe traumatic brain injury. Exp. Ther. Med. 2017, 13, 3613–3618. [CrossRef]
73. Harris, V.K.; Stark, J.; Vyshkina, T.; Blackshear, L.; Joo, G.; Stefanova, V.; Sara, G.; Sadiq, S.A. Phase i trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. Ebihemio 2018, 29, 23–30. [CrossRef]
74. Erhardt, A.; Rizzio, S.; Mertens, J.; Edenhofer, F. Take the shortcut—direct conversion of somatic cells into induced neural stem cells and their biomedical applications. FEBS Lett. 2019, 593, 3353–3369. [CrossRef]
75. Liu, D.H.; Manaph, N.P.A.; Al-Hawwas, M.; Zhou, X.F.; Liao, H. Small molecules for neural stem cell induction. Stem Cells Dev. 2018, 27, 297–312. [CrossRef] [PubMed]
76. Li, Z.; Zhao, W.; Liu, W.; Zhou, Y.; Jia, J.; Yang, L. Transplantation of placenta-derived mesenchymal stem cell-induced neural stem cells to treat spinal cord injury. Neural Regen. Res. 2014, 9, 2197–2204.
77. Bago, J.R.; Alfonso-Peccio, A.; Okolie, O.; Dumitru, R.; Rinkenbaugh, A.; Baldwin, A.S.; Miller, C.R.; Magness, S.T.; Hingtgen, S.D. Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nat. Commun. 2016, 7, 10593. [CrossRef]
78. Yamashita, T.; Liu, W.; Matsumura, Y.; Miyagi, R.; Zhai, Y.; Kusaki, M.; Hishikawa, N.; Ohta, Y.; Kim, S.M.; Kwak, T.H.; et al. Novel therapeutic transplantation of induced neural stem cells for stroke. Cell Transpl. 2017, 26, 461–467. [CrossRef]
79. Vondervalde, I.; Azimi, A.; Rolvink, G.; Ahlforh, J.E.; Shoichet, M.S.; Morshed, C.M. Transplantation of directly reprogrammed human neural precursor cells following stroke promotes synaptogenesis and functional recovery. Stroke Transl. Res. 2020, 11, 93–107. [CrossRef] [PubMed]
80. Mazzini, L.; Gelati, M.; Proftco, D.C.; Soraru, G.; Ferrari, D.; Copetti, M.; Muzi, G.; Ricciolino, C.; Carletti, S.; Giorgi, C.; et al. Results from phase i clinical trial with intraspinol injection of neural stem cells in amyotrophic lateral sclerosis: A long-term outcome. Stem Cell Transl. Med. 2019, 8, 887–897. [CrossRef]

81. Glass, J.D.; Hertzberg, V.S.; Boullis, N.M.; Riley, J.; Federici, T.; Polak, M.; Bordeaux, J.; Fournier, C.; Johe, K.; Hazel, T.; et al. Transplantation of spinal cord-derived neural stem cells for als: Analysis of phase 1 and 2 trials. Neurology 2016, 87, 392–400. [CrossRef]

82. Madrazo, I.; Kopyov, O.; Avila-Rodriguez, M.A.; Ostrosky, F.; Carrasco, H.; Kopyov, A.; Avendano-Estrada, A.; Jimenez, F.; Magallon, E.; Zamorano, C.; et al. Transplantation of human neural progenitor cells (npc) into putamina of parkinsonian patients: A case series study, safety and efficacy four years after surgery. Cell Transpl. 2019, 28, 269–285. [CrossRef]

83. Levi, A.D.; Anderson, K.D.; Okonkwo, D.O.; Park, P.; Bryce, T.N.; Kurpad, S.N.; Aarabi, B.; Hsieh, J.; Gant, K. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J. Neurotraum. 2019, 36, 891–902. [CrossRef] [PubMed]

84. Levi, A.D.; Okonkwo, D.O.; Park, P.; Jenkins, A.L.; Kurpad, S.N.; Parr, A.M.; Ganju, A.; Aarabi, B.; Kim, D.; Casha, S.; et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery 2018, 82, 562–575. [CrossRef]

85. Shin, J.C.; Kim, K.N.; Yoo, J.; Kim, I.S.; Yun, S.; Lee, H.; Jung, K.; Hwang, K.; Kim, M.; Lee, I.S.; et al. Clinical trial of human fetal brain-derived neural stem cell/progenitor cell transplantation in patients with traumatic spinal cord spinal cord injury. Neur. Plast. 2015, 2015, 630932. [CrossRef]

86. Abeysinghe, H.C.S.; Bokhari, L.; Quigley, A.; Choolani, M.; Chan, J.; Dusting, G.; Crook, J.M.; Kobayashi, N.R.; Roulston, C.L. Pre-differentiation of human neural stem cells into gabaergic neurons prior to transplant results in greater repopulation of the damaged brain and accelerates functional recovery after transient ischemic stroke. Stem Cell Res. Ther. 2015, 6, 186. [CrossRef] [PubMed]

87. Jonsson, M.E.; Ono, Y.; Bjorklund, A.; Thompson, L.H. Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis. Exp. Neurol. 2009, 219, 341–354. [CrossRef] [PubMed]

88. Watmuff, B.; Pouton, C.W.; Haynes, J.M. In vitro maturation of dopaminergic neurons derived from mouse embryonic stem cells: Implications for transplantation. PLoS ONE 2012, 7, e31999. [CrossRef]

89. Payne, S.L.; Anandakumaran, P.N.; Varga, B.V.; Morshead, C.M.; Nagy, A.; Shoichet, M.S. In vitro maturation of human ipsc-derived neuroepithelial cells influences transplant survival in the stroke-injured rat brain. Tissue Eng. Part A 2018, 24, 351–360. [CrossRef]

90. Fortin, J.M.; Azari, H.; Zheng, T.; Darioosh, R.P.; Schmoll, M.E.; Vedam-Mai, V.; Deleyrolle, L.P.; Reynolds, B.A. Transplantation of defined populations of differentiated human neural stem cell progeny. Sci. Rep. 2016, 6, 23579. [CrossRef] [PubMed]

91. Qiu, L.; Liao, M.C.; Chen, A.K.; Wei, S.; Xie, S.; Reuveny, S.; Zhou, Z.D.; Hunziker, W.; Tan, E.K.; Oh, S.K.W.; et al. Immature midbrain dopaminergic neurons derived from floor-plate method improve cell transplantation therapy efficacy for parkinson’s disease. Stem Cells Transl. Med. 2017, 6, 1803–1814. [CrossRef] [PubMed]

92. Lee, H.; Lee, H.Y.; Lee, B.E.; Gerovska, D.; Park, S.Y.; Zaehres, H.; Arauzo-Bravo, M.J.; Kim, J.L.; Ha, Y.; Scholer, H.R.; et al. Sequentially induced motor neurons from human fibroblasts facilitate locomotor recovery in a rodent spinal cord injury model. Elife 2020, 9, e52069. [CrossRef] [PubMed]

93. Liu, D.H.; Ryckho, G.; Al-Hawwas, I.; ul Manaph, N.P.; Zhou, F.N.; Bobrovskaya, L.; Liao, H.; Zhou, X.F. Conversion of immature hippocampal and neuronal progenitor cells-conditioned medium in experimental ischemic stroke in rats. Int. J. Mol. Sci. 2021, 22, 4694. [CrossRef]

94. Thiruvalluvan, A.; Czepiel, M.; Kap, Y.A.; Mantinching-Otter, I.; Vainchtein, I.; Kuipers, J.; Bijlard, M.; Baron, W.; Giepmans, B.; Bruck, W.; et al. Survival and functionality of human induced pluripotent stem cell-derived oligodendrocytes in a nonhuman primate model for multiple sclerosis. Stem Cells Transl. Med. 2016, 5, 1550–1561. [CrossRef]

95. Fuhrmann, T.; Tam, R.Y.; Ballarin, B.; Coles, B.; Elliott Donaghue, I.; van der Kooy, D.; Nagy, A.; Tator, C.H.; Morshed, C.M.; Shoichet, M.S. Injectable hydrogel promotes early survival of induced pluripotent stem cell-derived oligodendrocytes and attenuates longterm teratoma formation in a spinal cord injury model. Biomaterials 2016, 83, 23–36. [CrossRef]

96. Kawabata, S.; Takano, M.; Numasawa-Kuroiwa, Y.; Itakura, G.; Kobayashi, Y.; Nishiyama, Y.; Sugai, K.; Nishimura, S.; Iwai, H.; Isoda, M.; et al. Grafted human ips cell-derived oligodendrocyte precursor cells contribute to robust remyelination of demyelinated axons after spinal cord injury. Stem Cell Rep. 2016, 6, 1–8. [CrossRef]

97. Keirstead, H.S.; Blakemore, W.F. Identification of post-mitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord. J. Neuropathol. Exp. Neurol. 1997, 56, 1191–1201. [CrossRef]

98. Targett, M.; Sussman, J.; Scolding, N.; O’Leary, M.T.; Compston, D.A.; Blakemore, W.F. Failure to achieve remyelination of demyelinated rat axons following transplantation of glial cells obtained from the adult human brain. Neuropathol. Appl. Neurobiol. 1996, 22, 199–206. [CrossRef]

99. Albert, K.; Niskanen, J.; Kaivala, S.; Lehtonen, S. Utilising induced pluripotent stem cells in neurodegenerative disease research: Focus on glia. Int. J. Mol. Sci. 2021, 22, 4334. [CrossRef] [PubMed]
101. Ricci, G.; Volpi, L.; Pasquali, L.; Petrozzi, L.; Siciliano, G. Astrocyte-neuron interactions in neurological disorders. *J. Biol. Phys.* 2009, 35, 317–336. [CrossRef] [PubMed]

102. Silver, J.; Miller, J.H. Regeneration beyond the glial scar. *Nat. Rev. Neurosci.* 2004, 5, 146–156. [CrossRef] [PubMed]

103. Li, K.; Javed, E.; Scura, D.; Hala, T.J.; Seetharam, S.; Falnikar, A.; Richard, J.P.; Chorath, A.; Maragakis, N.J.; Wright, M.C.; et al. Human ips cell-derived astrocyte transplants preserve respiratory function after spinal cord injury. *Exp. Neurol.* 2015, 271, 479–492. [CrossRef] [PubMed]

104. Davies, S.J.; Shih, C.H.; Noble, M.; Mayer-Proeschel, M.; Davies, J.E.; Proschel, C. Transplantation of specific human astrocytes promotes functional recovery after spinal cord injury. *PLoS ONE* 2011, 6, e17328. [CrossRef]

105. Nakao, N.; Shintani-Mizushima, A.; Kakishita, K.; Itakura, T. The ability of grafted human sympathetic neurons to synthesize and store dopamine: A potential mechanism for the clinical effect of sympathetic neuron autografts in patients with parkinson’s disease. *Exp. Neurol.* 2004, 188, 65–73. [CrossRef]

106. Freed, C.R.; Greene, P.E.; Breeze, R.E.; Tsai, W.Y.; Dumouchel, W.; Kao, R.; Dillon, S.; Winfield, H.; Culver, S.; Trojanowski, J.Q.; et al. Transplantation of embryonic dopamine neurons for severe parkinson’s disease. *N. Engl. J. Med.* 2001, 344, 710–719. [CrossRef]

107. Kondziolka, D.; Wechsler, L.; Goldstein, S.; Meltzer, C.; Thulborn, K.R.; Gebel, J.; Jannetta, P.; DeCesare, S.; Elder, E.M.; McGrogan, M.; et al. Transplantation of cultured human neuronal cells for patients with stroke. *Neurology* 2000, 55, 565–569. [CrossRef]

108. Ruzicka, J.; Kulijewicz-Nawrot, M.; Rodrigez-Arellano, J.J.; Jendelova, P.; Sykova, E. Mesenchymal stem cell transplantation for neurodegenerative diseases. *Cell Transpl.* 2008, 17, 1103–1113. [CrossRef]

109. Asgari Taei, A.; Dargahi, L.; Nasoohi, S.; Hassanzadeh, G.; Kadivar, M.; Farahmandfar, M. The conditioned medium of human umbilical mesenchymal stem cells from wharton’s jelly ameliorates mouse spinocerebellar ataxia type 1. *Xenografting of human umbilical mesenchymal stem cells from wharton’s jelly ameliorates mouse spinocerebellar ataxia type 1. Transl. Neurodegener.* 2019, 8, 29. [CrossRef] [PubMed]

110. Silver, J.; Miller, J.H. Regeneration beyond the glial scar. *Nat. Rev. Neurosci.* 2004, 5, 146–156. [CrossRef] [PubMed]

111. Li, K.; Javed, E.; Scura, D.; Hala, T.J.; Seetharam, S.; Falnikar, A.; Richard, J.P.; Chorath, A.; Maragakis, N.J.; Wright, M.C.; et al. Human ips cell-derived astrocyte transplants preserve respiratory function after spinal cord injury. *Exp. Neurol.* 2015, 271, 479–492. [CrossRef] [PubMed]

112. Zhang, L.; Wang, L.M.; Chen, W.W.; Ma, Z.; Han, X.; Liu, C.M.; Cheng, X.; Shi, W.; Guo, J.J.; Qin, J.B.; et al. Neural differentiation promotes functional recovery in an intracerebral hemorrhage rat model. *Sci. Rep.* 2015, 5, 188. [CrossRef] [PubMed]

113. Lo Furno, D.; Mannino, G.; Giuffrida, R. Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases. *J. Cell Physiol.* 2021, 236, 1967–1979. [CrossRef]

114. Li, K.; Javed, E.; Scura, D.; Hala, T.J.; Seetharam, S.; Falnikar, A.; Richard, J.P.; Chorath, A.; Maragakis, N.J.; Wright, M.C.; et al. Human ips cell-derived astrocyte transplants preserve respiratory function after spinal cord injury. *Exp. Neurol.* 2015, 271, 479–492. [CrossRef] [PubMed]

115. Mohammadi, A.; Maleki-Jamshid, A.; Milan, P.B.; Ebrahimzadeh, K.; Faghihi, F.; Joghataei, M.T. Intrahippocampal transplantation of undifferentiated human chorionic mesenchymal stem cells does not improve learning and memory in the rat model of sporadic alzheimer disease. *Curr. Stem Cell Res. Ther.* 2019, 14, 184–190. [CrossRef] [PubMed]

116. Das, M.; Mayilsamy, K.; Tang, X.L.; Han, J.Y.; Foran, E.; Willing, A.E.; Mohapatra, S.S.; Mohapatra, S. Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats. *Sci. Rep.* 2019, 9, 13646. [CrossRef] [PubMed]

117. Sun, S.J.; Zhang, Q.; Li, M.; Gao, P.; Huang, K.; Beejadhursting, R.; Jiang, W.; Lei, T.; Zhu, M.X.; Shu, K. Gdnf promotes survival and therapeutic efficacy of human adipose-derived mesenchymal stem cells in a mouse model of parkinson’s disease. *Cell Transpl.* 2020, 29, 963689720908512. [CrossRef] [PubMed]
124. Guo, M.G.; Wu, L.X.; Song, Z.Y.; Yang, B. Enhancement of neural stem cell proliferation in rats with spinal cord injury by a combination of repetitive transcranial magnetic stimulation (rtms) and human umbilical cord blood mesenchymal stem cells (hucb-mscs). Med. Sci. Monit. 2020, 26, e924445. [CrossRef]

125. Deng, W.S.; Yang, K.; Liang, B.; Liu, Y.F.; Chen, X.Y.; Zhang, S. Collagen/heparin sulfate scaffold combined with mesenchymal stem cells treatment for canines with spinal cord injury: A pilot feasibility study. J Orthop. Surg. 2021, 29, 23094990211012293. [CrossRef]

126. Oshita, J.; Okazaki, T.; Mitsuhashi, T.; Imura, T.; Nakagawa, K.; Otsuka, T.; Kurose, T.; Tamura, T.; Abiko, M.; Takeda, M.; et al. Early transplantation of human cranial bone-derived mesenchymal stem cells enhances functional recovery in ischemic stroke model rats. Neurol. Med. Chir. 2020, 60, 83–93. [CrossRef] [PubMed]

127. Yamaguchi, S.; Horie, N.; Satoh, K.; Ishikawa, T.; Morisada, H.; Maeda, H.; Fukuda, Y.; Ishizaka, S.; Hu, T.; Morofuji, Y.; et al. Age of donor of human umbilical cord stem cells affects structural and functional recovery after cell therapy following ischemic stroke. J. Cerebr. Blood Flow Met. 2018, 38, 1199–1212. [CrossRef] [PubMed]

128. Ko, P.W.; Park, S.; Kang, K.; Lim, Y.H.; Kim, S.R.; Suk, K.; Kim, K.S.; Lee, H.W. Human allogeneic bone marrow-derived mesenchymal stem cell therapy for cerebellar ataxia: A case report. Medicine 2021, 57, 334. [CrossRef]

129. Siwek, T.; Zejierska-Wozniak, K.; Maksymowicz, S.; Barczewska, M.; Sowa, M.; Badowska, W.; Maksymowicz, W. Repeat administration of bone marrow-derived mesenchymal stem cells for treatment of amyotrophic lateral sclerosis. Med. Sci. Monit. 2020, 26, e927484. [CrossRef]

130. Yang, Y.; Pang, M.; Du, C.; Liu, Z.Y.; Chen, Z.H.; Wang, N.X.; Zhang, L.M.; Chen, Y.Y.; Mo, J.; Dong, J.W.; et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: A phase 1/2 pilot study. Cytotherapy 2021, 23, 57–64. [CrossRef]

131. Deng, W.S.; Ma, K.; Liang, B.; Liu, X.Y.; Xu, H.Y.; Zhang, J.; Shi, H.Y.; Sun, H.T.; Chen, X.Y.; Zhang, S. Collagen scaffold combined with human umbilical-cord mesenchymal stem cells transplantation for acute complete spinal cord injury. Neural Regen. Res. 2020, 15, 1686–1700.

132. Phedy, P.; Djaja, Y.P.; Gatam, L.; Kusnadi, Y.; Wirawan, R.P.; Tobing, I.M.S.; Subakir, N.; Mappulilu, A.; Prawira, M.A.; Yauwenas, R.; et al. Motoric recovery after transplantation of bone marrow derived mesenchymal stem cells in chronic spinal cord injury: A case report. Am. J. Case Rep. 2019, 20, 1299–1304. [CrossRef]

133. Xiao, Z.F.; Tang, F.W.; Zhao, Y.N.; Han, G.; Yin, N.; Li, X.; Chen, B.; Han, S.F.; Jiang, X.F.; Yun, C.; et al. Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with neuroregen scaffolds and mesenchymal stem cells. Cell Transpl. 2018, 27, 907–915. [CrossRef]

134. Hur, J.W.; Cho, T.H.; Park, D.H.; Lee, J.B.; Park, J.Y.; Chung, Y.G. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: A human trial. J. Spinal Cord. Med. 2016, 39, 655–664. [CrossRef]

135. Gu, J.W.; Huang, L.; Zhang, C.; Wang, Y.; Zhang, R.B.; Tu, Z.L.; Wang, H.D.; Zhou, X.H.; Xiao, Z.S.; Liu, Z.G.; et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: A randomized, controlled trial. Stem Cell Res. Ther. 2020, 11, 43. [CrossRef] [PubMed]

136. Okur, S.C.; Erdogan, S.; Demir, C.S.; Gunel, G.; Karaoz, E. The effect of umbilical cord-derived mesenchymal stem cell transplantation in a patient with traumatic brain injury: A pilot study. Turk. Neurosurg. 2020, 30, 914–922. [CrossRef] [PubMed]

137. Steinberg, G.K.; Kondziolka, D.; Wechsler, L.R.; Lunsford, L.D.; Kim, A.S.; Johnson, J.N.; Bates, D.; Poggio, G.; Case, C.; McGrogan, M.; et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (sb623): A phase 1/2a study. J. Neurosurg. 2019, 131, 1462–1472. [CrossRef] [PubMed]

138. Xie, B.C.; Gu, P.; Wang, W.T.; Dong, C.; Zhang, L.N.; Zhang, J.; Liu, H.M.; Qiu, F.C.; Han, R.; Zhang, Z.Q.; et al. Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy. Am. J. Transl. Res. 2016, 8, 3241–3250.
144. Riordan, N.H.; Morales, I.; Fernandez, G.; Allen, N.; Fearnot, N.E.; Leckrone, M.E.; Markovich, D.J.; Mansfield, D.; Avila, D.; Patel, A.N.; et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. *J. Transl. Med.* 2018, 16, 57. [CrossRef]

145. Cohen, J.A.; Imrey, P.B.; Planchon, S.M.; Bermel, R.A.; Fisher, E.; Fox, R.J.; Bar-Or, A.; Sharp, S.L.; Skaramagas, T.T.; Jagodnik, P.; et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. *Mult. Scler.* 2018, 24, 501–511. [CrossRef]

146. Milczarek, O.; Jarocha, D.; Starowicz-Filip, A.; Kwiatkowski, S.; Badyra, B.; Majka, M. Multiple autologous bone marrow-derived cd271(+) mesenchymal stem cell transplantation overcomes drug-resistant epilepsy in children. *Stem Cell Transl. Med.* 2018, 7, 20–33. [CrossRef]

147. Venkataramana, N.K.; Kumar, S.K.V.; Balaraju, S.; Radhakrishnan, R.C.; Bansal, A.; Dixit, A.; Rao, D.K.; Das, M.; Jan, M.; Gupta, P.K.; et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. *Transl. Res.* 2010, 155, 62–70. [CrossRef] [PubMed]

148. Lan, X.; Sun, Z.; Chu, C.; Boltze, J.; Li, S. Dental pulp stem cells: An attractive alternative for cell therapy in ischemic stroke. *Front. Neurol.* 2019, 10, 824. [CrossRef]

149. Gioventu, S.; Andriolo, G.; Bonino, F.; Frasca, S.; Lazzari, L.; Montelatici, E.; Santoro, F.; Rebulla, P. A novel method for banking dental pulp stem cells. *Transfus. Apher. Sci.* 2012, 47, 199–206. [CrossRef] [PubMed]

150. Ma, L.; Makino, Y.; Yamaza, H.; Akiyama, K.; Hoshino, Y.; Song, G.T.; Kukita, T.; Nonaka, K.; Shi, S.T.; Yamaza, T. Cryopreserved dental pulp tissues of exfoliated deciduous teeth is a feasible stem cell resource for regenerative medicine. *PLoS ONE* 2012, 7, e51777. [CrossRef] [PubMed]

151. Ueda, T.; Inden, M.; Ito, T.; Kurita, H.; Hozumi, I. Characteristics and therapeutic potential of dental stem cells on neurodegenerative diseases. *Front. Neurosci.* 2018, 12, 407. [CrossRef] [PubMed]

152. Mead, B.; Logan, A.; Berry, M.; Leadbeater, W.; Scheven, B.A. Paracrine-mediated neuroprotection and neuritogenesis of axotomised retinal ganglion cells by human dental pulp stem cells: Comparison with human bone marrow and adipose-derived mesenchymal stem cells. *PLoS ONE* 2012, 9, e109305. [CrossRef] [PubMed]

153. Wang, J.; Zuzzio, K.; Walker, C.L. Systemic dental pulp stem cell therapy secretome in a mouse model of amyotrophic lateral sclerosis. *Brain Sci.* 2019, 9, 165. [CrossRef] [PubMed]

154. Miura, M.; Gronthos, S.; Zhao, M.; Lu, B.; Fisher, L.W.; Robey, P.G.; Shi, S. Shed: Stem cells from human exfoliated deciduous teeth. *Proc. Natl. Acad. Sci. USA* 2003, 100, 5807–5812. [CrossRef] [PubMed]

155. Govindasamy, V.; Abdullah, A.N.; Ronald, V.S.; Musa, S.; Ab Aziz, Z.A.; Zain, R.B.; Totey, S.; Bhonde, R.R.; Abu Kasim, N.H. Inherent differential propensity of dental pulp stem cells derived from human deciduous and permanent teeth. *J. Endod.* 2010, 36, 1504–1515. [CrossRef]

156. Inoue, T.; Sugiyama, M.; Hattori, H.; Wakita, H.; Wakabayashi, T.; Ueda, M. Stem cells from human exfoliated deciduous tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. *Tissue Eng. Part A* 2013, 19, 24–29. [CrossRef] [PubMed]

157. Chen, Y.R.; Lai, P.L.; Chien, Y.; Lee, P.H.; Lai, Y.H.; Ma, H.I.; Shiau, C.Y.; Wang, K.C. Improvement of impaired motor functions by human dental exfoliated deciduous teeth-derived conditioned medium to tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. *Tissue Eng. Part A* 2018, 24, 20–33. [CrossRef] [PubMed]

158. Li, Y.; Yang, Y.Y.; Ren, J.L.; Xu, F.; Chen, F.M.; Li, A. Exosomes secreted by stem cells from human exfoliated deciduous teeth enhance axonal regeneration. *PLoS ONE* 2019, 14, 108. [CrossRef] [PubMed]

159. Alraies, A.; Waddington, R.J.; Sloan, A.J.; Moseley, R. Evaluation of dental pulp stem cell heterogeneity and behaviour in 3d type i collagen gels. *Biomed. Res. Int.* 2020, 2020, 3034727. [CrossRef] [PubMed]

160. Kunimatsu, R.; Nakajima, K.; Awada, T.; Tsuka, Y.; Abe, T.; Ando, K.; Hiraki, T.; Kimura, A.; Tanimoto, K. Comparative characterization of stem cells from human exfoliated deciduous teeth, dental pulp, and bone marrow-derived mesenchymal stem cells. *Stem Cell Res. Ther.* 2018, 9, 155. [CrossRef] [PubMed]

161. Kuroda, Y.; Kitada, M.; Wakao, S.; Nishikawa, K.; Tanimura, Y.; Makinoshima, H.; Goda, M.; Akashi, H.; Inutsuka, A.; Niwa, A.; et al. Unique multipotent cells in adult human mesenchymal stem cell populations. *Proc. Natl. Acad. Sci. USA* 2010, 107, 8639–8643. [CrossRef] [PubMed]

162. Alfraies, A.; Waddington, R.J.; Sloan, A.J.; Moseley, R. Evaluation of dental pulp stem cell heterogeneity and behaviour in 3d type i collagen gels. *Biomed. Res. Int.* 2020, 2020, 3034727. [CrossRef] [PubMed]

163. Leng, Z.; Sun, D.; Huang, Z.; Tadmori, I.; Chiang, N.; Kethidi, N.; Sabra, A.; Kushida, Y.; Fu, Y.S.; Dezawa, M.; et al. Quantitative analysis of ssea3+ cells from human umbilical cord after magnetic sorting. *Cell Transpl.* 2019, 28, 907–923. [CrossRef] [PubMed]

164. Kuroda, Y.; Wakao, S.; Kitada, M.; Murakami, T.; Nojima, M.; Dezawa, M. Isolation, culture and evaluation of multilineage-differentiating stem-enduring (muse) cells. *Nat. Protoc.* 2013, 8, 1391–1415. [CrossRef]

165. Wakao, S.; Kitada, M.; Kuroda, Y.; Shigemoto, T.; Matsuse, D.; Akashi, H.; Tanimura, Y.; Tsukiyama, K.; Kikuchi, T.; Goda, M.; et al. Multilineage-differentiating stress-enduring (muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. *Proc. Natl. Acad. Sci. USA* 2011, 108, 9875–9880. [CrossRef] [PubMed]

166. Byrne, J.A.; Nguyen, H.N.; Reijo Pera, R.A. Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts. *PLoS ONE* 2009, 4, e7118. [CrossRef] [PubMed]

167. Dezawa, M. Muse cells provide the pluripotency of mesenchymal stem cells: Direct contribution of muse cells to tissue regeneration. *Cell Transpl.* 2016, 25, 849–861. [CrossRef] [PubMed]
167. Suzuki, T.; Sato, Y.; Kushida, Y.; Tsuji, M.; Wakao, S.; Ueda, K.; Imai, K.; Itani, Y.; Shimizu, S.; Hida, H.; et al. Intravenously delivered multiligneage-differentiating stress enduring cells dampen excessive glutamate metabolism and microglial activation in experimental perinatal hypoxic ischemic encephalopathy. *J. Cereb. Blood Flow Metab.* 2020, 41, 1707–1720. [CrossRef]

168. Ozuru, R.; Wakao, S.; Tsuji, T.; Ohara, N.; Matsuba, T.; Amuran, M.Y.; Isobe, J.; Iino, M.; Nishida, N.; Matsumoto, S.; et al. Rescue from stx2-producing e. ColI-associated encephalopathy by intravenous injection of muse cells in nod-scid mice. *Mol. Ther.* 2020, 28, 100–118. [CrossRef]

169. Yamashita, T.; Kushida, Y.; Wakao, S.; Tadokoro, K.; Nomura, E.; Omote, Y.; Takemoto, M.; Hishikawa, N.; Ohta, Y.; Dezawa, M.; et al. Therapeutic benefit of muse cells in a mouse model of amyotrophic lateral sclerosis. *Sci. Rep.* 2020, 10, 17102. [CrossRef]

170. Kajitani, T.; Endo, T.; Ibawuchi, N.; Inoue, T.; Takanashi, Y.; Abe, T.; Nilizuma, K.; Tominaga, T. Association of intravenous administration of human muse cells with deficit amelioration in a rat model of spinal cord injury. *J. Neurosurg. Spine* 2021, 34, 648–655. [CrossRef]

171. Watzlawick, R.; Rind, J.; Sena, E.S.; Brommer, B.; Zhang, T.; Koppe, M.A.; Dirnagl, U.; Macleod, M.R.; Howells, D.W.; Schwab, J.M. Olfactory ensheathing cell transplantation in experimental spinal cord injury: Effect size and reporting bias of 62 experimental treatments: A systematic review and meta-analysis. *PLoS Biol.* 2016, 14, e1002468. [CrossRef]

172. Urasavas, S.; Darici, H.; Karaoz, E. Olfactory ensheathing cells: Unique glial cells promising for treatments of spinal cord injury. *J. Neurosci. Res.* 2021, 99, 1579–1597. [CrossRef] [PubMed]

173. Chen, L.; Chen, D.; Xi, H.; Wang, Q.; Liu, Y.; Zhang, F.; Wang, H.; Ren, Y.; Xiao, J.; Wang, Y.; et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: Benefits from multiple transplantations. *Cell Transpl.* 2012, 21 (Suppl. 1), S65–S77. [CrossRef]

174. Chen, L.; Huang, H.; Xi, H.; Xie, Z.; Liu, R.; Jiang, Z.; Zhang, F.; Liu, Y.; Chen, D.; Wang, Q.; et al. Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: A randomized controlled clinical trial. *Cell Transpl.* 2010, 19, 185–191. [CrossRef] [PubMed]

175. Gilmour, A.D.; Reshamwala, R.; Wright, A.A.; Ekberg, J.A.K.; St John, J.A. Optimizing olfactory ensheathing cell transplantation for spinal cord injury repair. *J. Neurotrauma* 2020, 37, 817–829. [CrossRef]

176. Tabakow, P.; Jarmundowicz, W.; Czapiga, B.; Fortuna, W.; Miedzybrodzki, R.; Czyz, M.; Huber, J.; Szarek, D.; Okurowski, S.; Szewczyk, P.; et al. Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. *Cell Transpl.* 2013, 22, 1591–1612. [CrossRef] [PubMed]

177. Chen, L.; Huang, H.; Xi, H.; Zhang, F.; Liu, Y.; Chen, D.; Xiao, J. A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and schwann cells for the treatment of chronic complete spinal cord injuries. *Cell Transpl.* 2014, 23 (Suppl. 1), S35–S44. [CrossRef] [PubMed]

178. Tabakow, P.; Raisman, G.; Fortuna, W.; Czyz, M.; Huber, J.; Li, D.; Szewczyk, P.; Okurowski, S.; Miedzybrodzki, R.; Czapiga, B.; et al. Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging. *Cell Transpl.* 2014, 23, 1631–1655. [CrossRef]

179. Rao, Y.; Zhu, W.X.; Du, Z.Q.; Jia, C.X.; Du, T.X.; Zhao, Q.A.; Cao, X.Y.; Wang, Y.J. Effectiveness of olfactory ensheathing cell transplantation for treatment of spinal cord injury. *Genet. Mol. Res.* 2014, 13, 4124–4129. [CrossRef] [PubMed]

180. Rao, Y.; Zhu, W.; Guo, Y.; Jia, C.; Qi, R.; Qiao, R.; Cao, D.; Zhang, H.; Cui, Z.; Yang, L.; et al. Long-term outcome of olfactory ensheathing cell transplantation in six patients with chronic complete spinal cord injury. *Cell Transpl.* 2013, 22 (Suppl. 1), S21–S25. [CrossRef]

181. Rao, Y.; Zhu, W.; Liu, H.; Jia, C.; Zhao, Q.; Wang, Y. Clinical application of olfactory ensheathing cells in the treatment of spinal cord injury. *J. Int. Med. Res.* 2013, 41, 473–481. [CrossRef]

182. Wu, J.; Sun, T.; Ye, C.; Yao, J.; Zhu, B.; He, H. Clinical observation of fetal olfactory ensheathing glia transplantation (oegt) in patients with complete chronic spinal cord injury. *Cell Transpl.* 2012, 21 (Suppl. 1), S33–S37. [CrossRef] [PubMed]

183. Huang, H.; Xi, H.; Chen, L.; Zhang, F.; Liu, Y. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. *Cell Transpl.* 2012, 21 (Suppl. 1), S23–S31. [CrossRef] [PubMed]

184. Huang, H.; Chen, L.; Wang, H.; Xiu, B.; Li, B.; Wang, R.; Zhang, J.; Zhang, F.; Gu, Z.; Li, Y.; et al. Influence of patients’ age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. *Chin. Med. J.* 2003, 116, 1488–1491.

185. Copelan, E.A. Medical progress: Hematopoietic stem-cell transplantation. *N. Engl. J. Med.* 2006, 354, 1813–1826. [CrossRef]

186. Burman, J.; Tolf, A.; Hagglund, H.; Askmark, H. Autologous haematopoietic stem cell transplantation for neurological diseases. *J. Neurol. Neurosurg. Psychiatry* 2018, 89, 147–155. [CrossRef] [PubMed]

187. Mariottiini, A.; De Matteis, E.; Muraro, P.A. Haematopoietic stem cell transplantation for multiple sclerosis: Current status. *BioDrugs* 2020, 34, 307–325. [CrossRef]

188. Price, J. Cell therapy approaches to autism: A review of clinical trial data. *Mol. Autism* 2020, 11, 37. [CrossRef]

189. Ahn, S.Y.; Chang, Y.S.; Kim, Y.E.; Sung, S.J.; Sung, D.K.; Park, W.S. Mesenchymal stem cells transplantation attenuates brain injury and enhances bacterial clearance in escherichia coli meningesis in newborn rats. *Pediatr. Res.* 2018, 84, 778–785. [CrossRef]